<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7751407</article-id><article-id pub-id-type="pmid">33327806</article-id><article-id pub-id-type="doi">10.1080/14756366.2020.1862101</article-id><article-id pub-id-type="publisher-id">1862101</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3&#x003b2; inhibitors targeting breast cancer: design, synthesis, biological evaluation, and <italic>in silico</italic> studies</article-title><alt-title alt-title-type="left-running-head">W. M. Eldehna et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eldehna</surname><given-names>Wagdy M.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><contrib contrib-type="author"><name><surname>Al-Rashood</surname><given-names>Sara T.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Al-Warhi</surname><given-names>Tarfah</given-names></name><xref ref-type="aff" rid="AF0003">c</xref></contrib><contrib contrib-type="author"><name><surname>Eskandrani</surname><given-names>Razan O.</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Alharbi</surname><given-names>Amal</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>El Kerdawy</surname><given-names>Ahmed M.</given-names></name><xref ref-type="aff" rid="AF0004">d</xref><xref ref-type="aff" rid="AF0005">e</xref></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</institution>, <city>Kafr El-Sheikh</city>, <country>Egypt</country></aff><aff id="AF0002"><label>b</label><institution>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0003"><label>c</label><institution>Department of Chemistry, College of Science, Princess Nourah Bint Abdulrahman University</institution>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="AF0004"><label>d</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University</institution>, <city>Cairo</city>, <country>Egypt</country></aff><aff id="AF0005"><label>e</label><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, New Giza University</institution>, <city>Cairo</city>, <country>Egypt</country></aff></contrib-group><author-notes><fn id="AUFN1"><p content-type="appended text">Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1862101"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Wagdy M. Eldehna <email>wagdy2000@gmail.com</email><institution>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</institution>, <city>Kafr El-Sheikh</city>, <postal-code>33516</postal-code>, <country>Egypt</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>12</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="26">270</fpage><lpage>285</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1862101.pdf"/><abstract><title>Abstract</title><p>The serine/threonine protein kinases CDK2 and GSK-3&#x003b2; are key oncotargets in breast cancer cell lines, therefore, in the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3&#x003b2; inhibitors targeting breast cancer (<bold>5a&#x02013;g</bold>, <bold>7a&#x02013;h</bold>, and <bold>13a&#x02013;b</bold>). The <italic>N<sup>1</sup></italic>-unsubstituted oxindole derivatives, <bold>series 5</bold>, showed moderate to potent activity on both MCF-7 and T-47D breast cancer cell lines. Compounds <bold>5d&#x02013;f</bold> showed the most potent cytotoxic activity with IC<sub>50</sub> of 3.41, 3.45 and 2.27&#x02009;&#x003bc;M, respectively, on MCF-7 and of 3.82, 4.53 and 7.80&#x02009;&#x003bc;M, respectively, on T-47D cell lines, in comparison to the used reference standard (staurosporine) IC<sub>50</sub> of 4.81 and 4.34&#x02009;&#x003bc;M, respectively. On the other hand, the <italic>N<sup>1</sup></italic>-substituted oxindole derivatives, <bold>series 7</bold> and <bold>13</bold>, showed moderate to weak cytotoxic activity on both breast cancer cell lines. CDK2 and GSK-3&#x003b2; enzyme inhibition assay of <bold>series 5</bold> revealed that compounds <bold>5d</bold> and <bold>5f</bold> are showing potent dual CDK2/GSK-3&#x003b2; inhibitory activity with IC<sub>50</sub> of 37.77 and 52.75&#x02009;nM, respectively, on CDK2 and 32.09 and 40.13&#x02009;nM, respectively, on GSK-3&#x003b2;. The most potent compounds <bold>5d&#x02013;f</bold> caused cell cycle arrest in the G2/M phase in MCF-7 cells inducing cell apoptosis because of the CDK2/GSK-3&#x003b2; inhibition. Molecular docking studies showed that the newly synthesised <italic>N<sup>1</sup></italic>-unsubstituted oxindole hybrids have comparable binding patterns in both CDK2 and GSK-3&#x003b2;. The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2 and Asp133 and Val135, respectively, in GSK-3&#x003b2;. Whereas, in series <bold>7</bold> and <bold>13</bold>, the <italic>N<sup>1</sup></italic>-substitutions on the oxindole nucleus hinder the compounds from achieving these key interactions with hinge region amino acids what rationalises their moderate to low anti-proliferative activity.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Dual kinase inhibitors</kwd><kwd>CDK2/GSK-3&#x003b2; inhibitors</kwd><kwd>Benzofuran-2-carbohydrazide</kwd><kwd>Isatin</kwd><kwd>anticancer agents</kwd></kwd-group><counts><fig-count count="13"/><table-count count="6"/><page-count count="16"/><word-count count="11603"/></counts></article-meta></front><body><sec id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Protein kinases (PKs) represent the fifth largest human protein family comprising 518 proteins<xref rid="CIT0001" ref-type="bibr"><sup>1&#x02013;2</sup></xref>. They are key regulators of cell functions through cellular signalling modulation and complex biological functions coordination such as cell growth, differentiation, proliferation, metabolism, migration, and apoptosis (programmed cell death)<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref><sup>,</sup><xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;5</sup></xref>. PKs exert their functions through catalysing the transfer of the gamma-phosphate group of an ATP molecule onto a substrate protein hydroxyl group (substrate protein phosphorylation) accomplishing cellular signals transduction and amplification<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref>. According to the phosphorylated residue in the substrate protein, PKs are classified into tyrosine kinases (90 kinases) and serine/threonine kinases (385 kinases), with a small group of dual specificity kinases including MEK1 and MEK2 which could catalyse the phosphorylation of both tyrosine and threonine on target proteins<xref rid="CIT0006" ref-type="bibr"><sup>6&#x02013;7</sup></xref>.</p><p>The prominent and critical importance of PKs dictates strict regulation of their cellular levels and activities, therefore, PKs dysregulation contributes to several diseases such as cancer, metabolic disorders (such as diabetes), cardiovascular diseases, neurodegenerative diseases (such as Alzheimer&#x02019;s disease), inflammatory disorders and autoimmune diseases (such as rheumatoid arthritis)<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref>. The usage of PKs inhibitors is a promising strategy to manage their dysregulation in these diseases<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;11</sup></xref>. In cancer treatment, PK inhibitors represent a key class of targeted chemotherapy which is devoid of the common side effects of conventional cancer chemotherapy because they target cancer cells&#x02019; signalling pathways and microenvironment with minimum undesirable effects on normal cells<xref rid="CIT0012" ref-type="bibr"><sup>12&#x02013;15</sup></xref>.</p><p>Breast cancer is a very common cancer type all over the world, and despite of its possible early detection by advanced diagnostic techniques, breast cancer is still considered the leading cause of death among women worldwide<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;17</sup></xref>. Thus, there is a serious continuous demand for the discovery of more effective anti-breast cancer agents. Several studies reported the overexpression of several PKs in primary as well as in metastatic breast cancers such as vascular endothelial growth factor receptor (VEGFR)<xref rid="CIT0018" ref-type="bibr"><sup>18&#x02013;20</sup></xref>, fibroblast growth factor receptor (FGFR)<xref rid="CIT0020" ref-type="bibr"><sup>20&#x02013;21</sup></xref>, platelet-derived growth factor receptor (PDGFR)<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref>, cyclin dependent kinases (CDKs) and their activating cyclins<xref rid="CIT0023" ref-type="bibr"><sup>23&#x02013;27</sup></xref>, and glycogen synthase kinase 3&#x003b2; (GSK-3&#x003b2;)<xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;30</sup></xref> and references therein.</p><p>CDKs, a family of serine/threonine protein kinases, are involved in several cellular functions such as division, proliferation, apoptosis, and gene transcription. CDK1, CDK2, CDK4 and CDK6 subtypes are responsible for the regulation of cell-cycle progression in its different phases, moreover, they play a pivotal role in cancer cell continuous proliferation<xref rid="CIT0031" ref-type="bibr"><sup>31&#x02013;33</sup></xref>. CDK2 subtype, specifically, received a great attention as a therapeutic target for cancer treatment due to its key role in several cellular processes upon complexation with its activating cognate, cyclin A or E, in addition, dysregulation of CDK2 or its cyclin partners was detected in various cancers such as ovarian, lung, pancreatic carcinomas, melanoma as well as breast cancer <xref rid="CIT0023" ref-type="bibr"><sup>23&#x02013;27</sup></xref><sup>,</sup><xref rid="CIT0034" ref-type="bibr"><sup>34&#x02013;37</sup></xref>. The impact of CDK2 inhibition on cancer cells confirmed the validity of CDK2 as a promising anticancer drug target, therefore, many CDK2 inhibitors have been progressed through clinical trials (<xref ref-type="fig" rid="F0001">Figure 1</xref>)<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>. In particular, CDK2 inhibition was found to effectively hinder breast cancer cells proliferation including those resistant to hormonal therapy<xref rid="CIT0039" ref-type="bibr"><sup>39&#x02013;41</sup></xref>.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>CDKs inhibitors in the clinical trial phases.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862101_F0001_B"/></fig><p>GSK-3, another serine/threonine protein kinase and an essential element of the WNT signalling pathway, contributes to several physiological processes ranging from gene expression to glycogen metabolism<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>. GSK-3 has two isozymes &#x003b1; and &#x003b2; encoded by two independent GSK-3 genes<xref rid="CIT0043" ref-type="bibr"><sup>43&#x02013;48</sup></xref>. GSK-3&#x003b2; is known as the &#x0201c;multi-tasking kinase&#x0201d; due to its participation in several signalling pathways<xref rid="CIT0049" ref-type="bibr"><sup>49</sup></xref>. Dysregulated activity of GSK-3&#x003b2; is associated with several diseases such as type 2 diabetes, heart disease, chronic inflammatory diseases, neurodegenerative diseases, and cancer, therefore, GSK-3&#x003b2; inhibition is a potential approach for the treatment of these diseases<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="CIT0050" ref-type="bibr"><sup>50</sup></xref>. GSK-3&#x003b2; is overexpressed in colon, pancreatic as well as breast cancers as it plays a key role in cancer cell proliferation and survival<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref>. The overexpression of GSK-3&#x003b2; correlates with poor prognosis in patients with breast cancer<xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;29</sup></xref>, moreover, aberrant nuclear accumulation of GSK-3&#x003b2; in five human breast cancer cell lines and in 70% of human breast carcinomas was reported<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>, furthermore, GSK-3&#x003b2; inhibition suppressed the viability of breast cancer cells <italic>in&#x000a0;vitro</italic>, moreover, GSK-3&#x003b2; inhibition overcomes chemoresistance in human breast cancer<xref rid="CIT0052" ref-type="bibr"><sup>52</sup></xref>.</p><p>The complex nature of cancer mandates the implementation of multitarget treatment strategies<xref rid="CIT0053" ref-type="bibr"><sup>53&#x02013;55</sup></xref>. Moreover, in several cancer types especially solid tumours, such as breast cancer, more than one PK is upregulated and contributes to carcinogenesis<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref><sup>,</sup><xref rid="CIT0056" ref-type="bibr"><sup>56</sup></xref>. Furthermore, drug resistance is commonly developed by target PK mutation, target PK amplification/overexpression, or through upregulation of alternative/downstream pathways<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref>. Thus, the use of multiple PK inhibitors is an emerging and appealing trend to overcome cancer development, progression, and resistance. A possible drawback of this approach is the pharmacokinetics (ADME) interference among the co-administered inhibitors, another concern is the potential toxicity of the used combination. To avoid these drawbacks, the design of small-molecules that are intentionally tailored to target more than one PK (multikinase inhibitors) was considered<xref rid="CIT0053" ref-type="bibr"><sup>53&#x02013;55</sup></xref><sup>,</sup><xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>. Multikinase inhibitors with favourable selectivity or multitarget selectivity (poly-specific inhibitors) might be more suitable for cancer treatment to balance efficacy and toxicity<xref rid="CIT0053" ref-type="bibr"><sup>53&#x02013;55</sup></xref><sup>,</sup><xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref><sup>,</sup><xref rid="CIT0058" ref-type="bibr"><sup>58</sup></xref>.</p><p>Dual CDKs/GSK-3&#x003b2; inhibition is a promising therapeutic approach to confront uncontrolled cancer cell proliferation<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="CIT0059" ref-type="bibr"><sup>59&#x02013;66</sup></xref>. In particular, CDK2 and GSK-3&#x003b2; share a high homologous sequence (33% amino acid identity) and are used as examples for the homological CMGC protein kinase family<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref><sup>,</sup><xref rid="CIT0064" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="CIT0067" ref-type="bibr"><sup>67&#x02013;75</sup></xref>. Therefore, designing dual CDK2/GSK-3&#x003b2; inhibitors as anticancer agents is an amenable and attractive strategy<xref rid="CIT0065" ref-type="bibr"><sup>65&#x02013;66</sup></xref>.</p><p>1<italic>H</italic>-indole-2,3-dione (isatin) is a privileged scaffold that emerged as a promising nucleus in medicinal chemistry demonstrating a broad range of pharmacological activities including antibacterial, anticonvulsant, antifungal, antiviral, as well as anticancer activity<xref rid="CIT0076" ref-type="bibr"><sup>76&#x02013;78</sup></xref>. Isatin derivatives exert their anticancer activity through several mechanisms such as inhibition and/or modulation of proteases, translation initiation, angiogenesis or tubulin polymerisation, moreover, PK inhibition is one of the key anticancer mechanisms of isatin derivatives<xref rid="CIT0076" ref-type="bibr"><sup>76&#x02013;78</sup></xref>. Several oxindole-based multikinase inhibitors (<xref ref-type="fig" rid="F0002">Figure 2</xref>) have been approved for cancer treatment such as sunitinib (2006) for gastrointestinal stromal tumour and renal cell carcinoma as PDGFR and VEGFR inhibitor<xref rid="CIT0079" ref-type="bibr"><sup>79</sup></xref>, and nintedanib (2014) for idiopathic pulmonary fibrosis as FGFR, PDGFR and VEGFR inhibitor<xref rid="CIT0080" ref-type="bibr"><sup>80</sup></xref>. Moreover, several oxindole derivatives have been designed and synthesised as inhibitors for diverse PKs such as FLT3 kinase<xref rid="CIT0081" ref-type="bibr"><sup>81</sup></xref>, VEGFR<xref rid="CIT0082" ref-type="bibr"><sup>82&#x02013;83</sup></xref>, polo-like kinase 4 (PLK4)<xref rid="CIT0084" ref-type="bibr"><sup>84</sup></xref>, aurora B kinase<xref rid="CIT0085" ref-type="bibr"><sup>85</sup></xref>, p90 ribosomal S6 protein kinase 2 (RSK2)<xref rid="CIT0086" ref-type="bibr"><sup>86</sup></xref>, microtubule affinity-regulating kinase 4 (MARK4)<xref rid="CIT0087" ref-type="bibr"><sup>87</sup></xref> as well as CDKs<xref rid="CIT0078" ref-type="bibr"><sup>78</sup></xref><sup>,</sup><xref rid="CIT0088" ref-type="bibr"><sup>88</sup></xref>, and GSK-3&#x003b2;<xref rid="CIT0059" ref-type="bibr"><sup>59</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Oxindole derivatives with multikinase activity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0002_C"/></fig><p>The naturally occurring oxindole derivative, indirubin, (<xref ref-type="fig" rid="F0002">Figure 2</xref>) has been identified as the main active ingredient of the traditional Chinese medicinal remedy, <italic>Dang Gui Long Hui Wan</italic> which is used to treat chronic myelocytic leukaemia (CML)<xref rid="CIT0064" ref-type="bibr"><sup>64</sup></xref><sup>,</sup><xref rid="CIT0066" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="CIT0089" ref-type="bibr"><sup>89</sup></xref>. Indirubin and its derivatives showed distinctive antiproliferative effect which is attributed to their inhibition of CDKs and GSK-3 through competing with ATP at the kinase domain<xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref><sup>,</sup><xref rid="CIT0090" ref-type="bibr"><sup>90&#x02013;93</sup></xref>.</p><p>Benzofuran is another privileged scaffold that demonstrated several desirable biological activities among which are analgesic, anti-inflammatory, antipyretic, antibacterial, antifungal, antiviral, antihyperglycemic, anti-hyperlipidemic, anti-oxidant, as well as anticancer activities<xref rid="CIT0094" ref-type="bibr"><sup>94&#x02013;96</sup></xref>. Benzofuran derivatives mediate their anticancer activity through several mechanism such as farnesyltransferase, angiogenesis, oestrogen receptor, human peptide deformylase, tubulin polymerisation, and carbonic anhydrase inhibition<xref rid="CIT0094" ref-type="bibr"><sup>94</sup></xref><sup>,</sup><xref rid="CIT0097" ref-type="bibr"><sup>97</sup></xref> and reference therein. Moreover, some benzofuran derivatives exert their anticancer activity through PK inhibition such as Pim-1<xref rid="CIT0098" ref-type="bibr"><sup>98</sup></xref>, mTOR signaling<xref rid="CIT0099" ref-type="bibr"><sup>99&#x02013;100</sup></xref>, Src kinase<xref rid="CIT0101" ref-type="bibr"><sup>101</sup></xref>, as well as GSK-3&#x003b2;<xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref> (<xref ref-type="fig" rid="F0003">Figure 3</xref>).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Benzofuran derivatives with GSK-3&#x003b2; inhibitory activity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0003_C"/></fig><p>Based on the reported PK inhibitory activity of isatin and benzofuran nuclei, specially, on the homologous CDK2 and GSK-3&#x003b2; kinases, a hybridisation strategy of these two privileged scaffolds was adapted to design dual CDK2/GSK-3&#x003b2; hybrid inhibitors which could target breast cancer. For the hybridisation strategy, the bioisosteric amido and uriedo moieties were used as linkers between the two nuclei, moreover, different substitution pattern and nature on the oxindole ring offering various electronic and lipophilic environments were introduced to study their impact on the activity (<xref ref-type="fig" rid="F0004">Figure 4</xref>). On account of the hydrophobic nature of the CDK2 binding site, it was anticipated that the grafting a hydrophobic substituent (such as Br) within the benzofuran motif could achieve a plenty of hydrophobic interactions.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Designed oxindole/benzofuran dual CDK2/GSK-3&#x003b2; hybrid inhibitors.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0004_C"/></fig><p>The newly synthesised compounds were experimentally evaluated for their anti-proliferative activities against breast cancer cell lines T-47D and MCF-7. Compounds showed promising anti-proliferative activity were tested for their potential dual CDK2/GSK-3&#x003b2; inhibitory activity, moreover, compounds showed prominent anti-proliferative activity and <italic>in&#x000a0;vitro</italic> PK inhibitory activity were investigated further by studying their effect on cell cycle progression and cell apoptosis. Furthermore, molecular docking studies were also performed to study the interaction of the newly synthesised hybrid compounds with CDK2 and GSK-3&#x003b2; kinase domain hot spots (key amino acids) to rationalise their biological activity and to reveal their probable binding mode.</p></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Results and discussion</title><sec id="S0002-S2001" disp-level="2"><label>2.1.</label><title>Chemistry</title><p>The synthetic strategies designed for the preparation of the target final compounds (<bold>5a-g</bold>, <bold>7a-h</bold> and <bold>13a-b</bold>) were illustrated in <xref ref-type="scheme" rid="s0001 s0002 s0003">Schemes 1&#x02013;3</xref>. In <xref ref-type="scheme" rid="s0001">Scheme 1</xref>, bromobenzofuran-2-carbohydrazide <bold>3</bold> was prepared <italic>via</italic> reaction of ethylbromacetate with 5-bromosalicylaldehyde <bold>1</bold> in acetonitrile to furnish ethyl 5-bromobenzofuran-2-carboxylate <bold>2</bold>. Thereafter, the ester functionality was subjected to hydrazinolysis via refluxing hydrazine hydrate to afford the key intermediate hydrazide <bold>3</bold>, further; this key intermediate <bold>3</bold> was condensed with different isatin derivatives <bold>4a-g</bold> in absolute ethyl alcohol with catalytic drops of glacial acetic acid to get the final novel compounds <bold>5a-g</bold>.</p><fig id="s0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of target compounds <bold>5a&#x02013;g</bold>; Reagents and conditions: (<bold>i</bold>) Ethyl bromoacetate/Acetonitrile/K<sub>2</sub>CO<sub>3</sub>/reflux 4&#x02009;h, (<bold>ii</bold>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 3&#x02009;h, (<bold>iii</bold>) Ethanol/glacial acetic acid (Cat.)/reflux 4&#x02013;7&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862101_SCH0001_B"/></fig><fig id="s0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthesis of target compounds <bold>7a-h</bold>; Reagents and conditions: (<bold>i</bold>) R<sub>2</sub>-Br/anhydrous DMF/K<sub>2</sub>CO<sub>3</sub>/reflux 4&#x02009;h, (<bold>ii</bold>) Ethanol/drops glacial acetic acid (Cat.)/reflux 4&#x02013;7&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862101_SCH0002_B"/></fig><fig id="s0003" orientation="portrait" position="float"><label>Scheme 3.</label><caption><p>Synthesis of target compounds <bold>13a-b</bold>; Reagents and conditions: (<bold>i</bold>) HCl/reflux 6&#x02009;h, (<bold>ii</bold>) (COCl)<sub>2</sub>/anhydrous toluene/reflux 5&#x02009;h, (<bold>iii</bold>) NaN<sub>3</sub>/acetone/stirring r.t. 1&#x02009;h, (<bold>iv</bold>) Dry toluene/reflux 1&#x02009;h. (<bold>v</bold>) NH<sub>2</sub>NH<sub>2</sub>.H<sub>2</sub>O/methanol/reflux 3&#x02009;h, (<bold>vi</bold>) Anhydrous toluene/reflux 4&#x02009;h.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862101_SCH0003_B"/></fig><p>In <xref ref-type="scheme" rid="s0002">Scheme 2</xref>, isatin derivatives <bold>4a</bold> and <bold>4d</bold> were subjected to <italic>N</italic>-alkylation in anhydrous DMF to furnish <italic>N</italic>-substituted isatin <bold>6a-h</bold>, which then condensed with the key intermediate <bold>3</bold> to afford target compounds <bold>7a-h</bold>.</p><p>In the last scheme, the ester moiety of 5-bromobenzofuran-2-carboxylate <bold>2</bold> succumbed to acidic hydrolysis to afford the acid analogue <bold>8</bold>, which was chlorinated with oxalyl chloride in toluene to get the acid chloride derivative <bold>9</bold> that reacted with NaN<sub>3</sub> in acetone to produce 5-bromobenzofuran-2-carbonyl azide <bold>10</bold>. The azide derivative <bold>10</bold> was subjugated to Curtius Rearrangement through heating in anhydrous toluene to furnish isocyanate analogue <bold>11</bold>. On the other hand, isatin derivatives <bold>6c</bold> and <bold>6e</bold> were condensed with hydrazine hydrate to release their hydrazone analogue <bold>12a</bold> and <bold>12&#x02009;b</bold>, respectively, which reacted with isocyanate analogue <bold>11</bold> to get the final target compounds <bold>13a-b</bold>.</p><p>The structures of all the synthesised compounds were confirmed under the basis of spectral and elemental analyses which were in full agreement with the proposed structures.</p></sec><sec id="S0002-S2002" disp-level="2"><label>2.2.</label><title>Biological evaluation</title><p>All the newly synthesised compounds were initially tested for their anti-proliferative activity against breast cancer cell lines T-47D and MCF-7 in MTT assay. Compounds showed promising anti-proliferative activity were tested for their PK inhibitory activity on the target kinases CDK-2 and GSK-3&#x003b2;. Furthermore, compounds showed prominent activity at cellular level and on enzymes were further evaluated for their effect on cell cycle progression and cell apoptosis in the breast cancer cell line MCF-7.</p><sec id="S0002-S2002-S3001" disp-level="3"><label>2.2.1.</label><title>In vitro <italic>anti-proliferative activity</italic></title><p>All the newly synthesised benzofuran-oxindole hybrids were screened for their <italic>in&#x000a0;vitro</italic> anti-proliferative activity against the breast cancer cell lines T-47D and MCF-7 using the MTT assay, and the results were compared with the pan-kinase inhibitor staurosporine as a reference standard <xref rid="CIT0102" ref-type="bibr"><sup>102</sup></xref>. The IC<sub>50</sub> values are presented in <xref rid="t0001" ref-type="table">Table 1</xref>.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p><italic>In vitro</italic> anti-proliferative activity of hybrids <bold>5a&#x02013;g</bold>, <bold>7a&#x02013;h</bold> and <bold>13a&#x02013;b</bold> against breast T-47D and MCF-7 cancer cell lines.<inline-graphic xlink:href="IENZ_A_1862101_ILG0001_B.jpg" content-type="black-white"/></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Comp.</th><th rowspan="2" align="center">R</th><th rowspan="2" align="center">R<sub>1</sub></th><th rowspan="2" align="center">R<sub>2</sub></th><th colspan="2" align="center">IC<sub>50</sub> (&#x000b5;M)<sup>a</sup><hr/></th></tr><tr><th align="center">MCF-7</th><th align="center">T-47D</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5a</bold></td><td align="center">H</td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">5.47&#x02009;&#x000b1;&#x02009;0.16</td><td align="char" char=".">9.67&#x02009;&#x000b1;&#x02009;0.31</td></tr><tr><td align="left"><bold>5b</bold></td><td align="center">F</td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">12.93&#x02009;&#x000b1;&#x02009;0.38</td><td align="char" char=".">1.27&#x02009;&#x000b1;&#x02009;0.04</td></tr><tr><td align="left"><bold>5c</bold></td><td align="center">Cl</td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">12.46&#x02009;&#x000b1;&#x02009;0.37</td><td align="char" char=".">6.03&#x02009;&#x000b1;&#x02009;0.19</td></tr><tr><td align="left"><bold>5d</bold></td><td align="center">Br</td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">3.41&#x02009;&#x000b1;&#x02009;0.10</td><td align="char" char=".">3.82&#x02009;&#x000b1;&#x02009;0.12</td></tr><tr><td align="left"><bold>5e</bold></td><td align="center">CH<sub>3</sub></td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">3.45&#x02009;&#x000b1;&#x02009;0.10</td><td align="char" char=".">4.53&#x02009;&#x000b1;&#x02009;0.14</td></tr><tr><td align="left"><bold>5f</bold></td><td align="center">OCH<sub>3</sub></td><td align="center">H</td><td align="center">&#x02013;</td><td align="char" char=".">2.27&#x02009;&#x000b1;&#x02009;0.06</td><td align="char" char=".">7.80&#x02009;&#x000b1;&#x02009;0.25</td></tr><tr><td align="left"><bold>5g</bold></td><td align="center">CH<sub>3</sub></td><td align="center">CH<sub>3</sub></td><td align="center">&#x02013;</td><td align="char" char=".">11.95&#x02009;&#x000b1;&#x02009;0.35</td><td align="char" char=".">6.65&#x02009;&#x000b1;&#x02009;0.21</td></tr><tr><td align="left"><bold>7a</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>3</sub></td><td align="char" char=".">10.43&#x02009;&#x000b1;&#x02009;1.01</td><td align="char" char=".">11.79&#x02009;&#x000b1;&#x02009;1.05</td></tr><tr><td align="left"><bold>7b</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>CH&#x02009;=&#x02009;CH<sub>2</sub></td><td align="char" char=".">2.64&#x02009;&#x000b1;&#x02009;0.07</td><td align="char" char=".">12.24&#x02009;&#x000b1;&#x02009;0.40</td></tr><tr><td align="left"><bold>7c</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">37.04&#x02009;&#x000b1;&#x02009;1.87</td><td align="char" char=".">43.27&#x02009;&#x000b1;&#x02009;2.39</td></tr><tr><td align="left"><bold>7d</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>COOC<sub>2</sub>H<sub>5</sub></td><td align="char" char=".">7.48&#x02009;&#x000b1;&#x02009;0.22</td><td align="char" char=".">18.99&#x02009;&#x000b1;&#x02009;0.62</td></tr><tr><td align="left"><bold>7e</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>Ph</td><td align="char" char=".">8.33&#x02009;&#x000b1;&#x02009;0.24</td><td align="char" char=".">11.80&#x02009;&#x000b1;&#x02009;0.38</td></tr><tr><td align="left"><bold>7f</bold></td><td align="center">H</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>CH<sub>2</sub>Ph</td><td align="char" char=".">24.67&#x02009;&#x000b1;&#x02009;0.72</td><td align="char" char=".">38.7&#x02009;&#x000b1;&#x02009;1.26</td></tr><tr><td align="left"><bold>7g</bold></td><td align="center">Br</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">24.82&#x02009;&#x000b1;&#x02009;0.73</td><td align="char" char=".">9.67&#x02009;&#x000b1;&#x02009;0.31</td></tr><tr><td align="left"><bold>7h</bold></td><td align="center">Br</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>Ph</td><td align="char" char=".">4.32&#x02009;&#x000b1;&#x02009;0.12</td><td align="char" char=".">1.72&#x02009;&#x000b1;&#x02009;0.04</td></tr><tr><td align="left"><bold>13a</bold></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">18.21&#x02009;&#x000b1;&#x02009;0.53</td><td align="char" char=".">3.22&#x02009;&#x000b1;&#x02009;0.10</td></tr><tr><td align="left"><bold>13b</bold></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">CH<sub>2</sub>Ph</td><td align="char" char=".">5.70&#x02009;&#x000b1;&#x02009;0.16</td><td align="char" char=".">10.88&#x02009;&#x000b1;&#x02009;0.35</td></tr><tr><td align="left"><bold>Staurosporine</bold></td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="char" char=".">4.81&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">4.34&#x02009;&#x000b1;&#x02009;0.14</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label><sup>a</sup></label><p>IC<sub>50</sub> values are the mean&#x02009;&#x000b1;&#x02009;SD of three separate experiments.</p></fn></table-wrap-foot></table-wrap><p>On MCF-7 cell line, the tested hybrids showed an IC<sub>50</sub> range of 2.27&#x02013;37.04&#x02009;&#x000b5;M, with compounds <bold>5d-f</bold>, <bold>7&#x02009;b</bold> and <bold>7&#x02009;h</bold> showing potent cytotoxic effect (3.41, 3.45, 2.27, 2.64 and 4.32&#x02009;&#x000b5;M, respectively) compared to the reference staurosporine which showed an IC<sub>50</sub> of 4.81&#x02009;&#x000b5;M. Compounds <bold>5a</bold>, <bold>7d</bold>, <bold>7e</bold> and <bold>13&#x02009;b</bold> showed moderate cytotoxic activity with IC<sub>50</sub> of 5.47, 7.48, 8.33 and 5.70, respectively, whereas, the rest of compounds showed weak cytotoxic activity with IC<sub>50</sub> higher than 10&#x02009;&#x000b5;M (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>On T-47D cell line, the tested compounds showed an IC<sub>50</sub> range of 1.27&#x02013;43.27&#x02009;&#x000b5;M, with compounds <bold>5&#x02009;b</bold>, <bold>5d-e</bold>,<bold>7h</bold> and <bold>13a</bold> showing potent cytotoxic effect (IC<sub>50</sub> of 1.27, 3.82, 4.53, 1.72 and 3.22&#x02009;&#x000b5;M, respectively) compared to the reference staurosporine which showed an IC<sub>50</sub> of 4.34&#x02009;&#x000b5;M. Compounds <bold>5a</bold>, <bold>5c</bold>, <bold>5f</bold>, <bold>5&#x02009;g</bold> and <bold>7&#x02009;g</bold> showed moderate cytotoxic activity with IC<sub>50</sub> of 9.67, 6.03, 7.80, 6.65 and 9.67&#x02009;&#x000b5;M, respectively, whereas, the rest of compounds showed weak cytotoxic activity with IC<sub>50</sub> higher than 10&#x02009;&#x000b5;M (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>These results indicate the superior cytotoxic activity of the <italic>N</italic>-unsubstituted isatin derivatives <bold>5a-g</bold> on both breast cancer cell lines with IC<sub>50</sub> range of 2.27&#x02013;12.93&#x02009;&#x000b5;M and 1.27&#x02013;9.67&#x02009;&#x000b5;M on MCF-7 and T-47D cell lines, respectively, which could be due to their better binding to the target kinases. Compounds <bold>5d&#x02013;f</bold> with Br, CH<sub>3</sub> and OCH<sub>3</sub> substituent on the isatin nucleus, respectively, showed the best cytotoxic activity (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>Series <bold>7</bold> showed moderate to weak cytotoxic activity on either or both cell lines, except for the <italic>N</italic>-benzylisatin hybrid <bold>7&#x02009;h</bold> which showed a potent cytotoxic activity on both cell lines with IC<sub>50</sub> of 4.32 and 1.72&#x02009;&#x000b5;M on MCF-7 and T-47D, respectively. These results indicate that the <italic>N</italic>-substitution at the isatin nucleus greatly affects the cytotoxic activity in the newly synthesised compounds mostly in a negative manner (<xref rid="t0001" ref-type="table">Table 1</xref>).</p><p>Worthy of note, replacing the amido group in compound <bold>7c</bold> and <bold>7e</bold> with the ureido moiety to afford <bold>13a</bold> and <bold>13&#x02009;b</bold> greatly enhanced the cytotoxic activity in both cell lines (37.04 and 8.33&#x02009;&#x000b5;M <italic>vs</italic> 18.21 and 5.70&#x02009;&#x000b5;M, respectively, in MCF-7) and (43.27 and 11.80&#x02009;&#x000b5;M <italic>vs</italic> 3.22 and 10.88&#x02009;&#x000b5;M, respectively, in T-47D) (<xref rid="t0001" ref-type="table">Table 1</xref>).</p></sec><sec id="S0002-S2002-S3002" disp-level="3"><label>2.2.2.</label><title>CDK2 and GSK-3&#x003b2; inhibitory activities</title><p>The most potent hybrids on breast cancer cell lines (<bold>series 5</bold>) were further evaluated biochemically for their kinase inhibitory activity on CDK-2 and GSK-3&#x003b2; using their Kinase Assay Kits, and were compared to the pan-kinase inhibitor staurosporine as a reference standard. The results were presented in <xref rid="t0002" ref-type="table">Table 2</xref>.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Inhibitory activities of compounds <bold>5a&#x02013;g</bold> against CDK2 and GSK-3&#x003b2;.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Comp.</th><th colspan="2" align="center">IC<sub>50</sub> (nM)<sup>a</sup><hr/></th></tr><tr><th align="center">CDK2</th><th align="center">GSK-3&#x003b2;</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5a</bold></td><td align="char" char="&#x000b1;">140.6&#x02009;&#x000b1;&#x02009;7.7</td><td align="char" char="&#x000b1;">136.9&#x02009;&#x000b1;&#x02009;7.5</td></tr><tr><td align="left"><bold>5b</bold></td><td align="char" char="&#x000b1;">52.46&#x02009;&#x000b1;&#x02009;2.9</td><td align="char" char="&#x000b1;">212.3&#x02009;&#x000b1;&#x02009;12</td></tr><tr><td align="left"><bold>5c</bold></td><td align="char" char="&#x000b1;">85.36&#x02009;&#x000b1;&#x02009;4.6</td><td align="char" char="&#x000b1;">102&#x02009;&#x000b1;&#x02009;5.6</td></tr><tr><td align="left"><bold>5d</bold></td><td align="char" char="&#x000b1;">37.77&#x02009;&#x000b1;&#x02009;2.1</td><td align="char" char="&#x000b1;">32.09&#x02009;&#x000b1;&#x02009;1.7</td></tr><tr><td align="left"><bold>5e</bold></td><td align="char" char="&#x000b1;">176.5&#x02009;&#x000b1;&#x02009;9.6</td><td align="char" char="&#x000b1;">80.75&#x02009;&#x000b1;&#x02009;4.4</td></tr><tr><td align="left"><bold>5f</bold></td><td align="char" char="&#x000b1;">52.75&#x02009;&#x000b1;&#x02009;2.9</td><td align="char" char="&#x000b1;">40.13&#x02009;&#x000b1;&#x02009;2.2</td></tr><tr><td align="left"><bold>5g</bold></td><td align="char" char="&#x000b1;">104.8&#x02009;&#x000b1;&#x02009;5.7</td><td align="char" char="&#x000b1;">75.54&#x02009;&#x000b1;&#x02009;4.1</td></tr><tr><td align="left"><bold>Staurosporine</bold></td><td align="char" char="&#x000b1;">38.5&#x02009;&#x000b1;&#x02009;2.1</td><td align="char" char="&#x000b1;">43.38&#x02009;&#x000b1;&#x02009;2.4</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><label><sup>a</sup></label><p>IC<sub>50</sub> values are the mean&#x02009;&#x000b1;&#x02009;SD of three separate experiments.</p></fn></table-wrap-foot></table-wrap><p>On CDK2, the tested compounds showed potent sub-micromolar inhibitory activity with IC<sub>50</sub> ranged from 37.80 to 177&#x02009;nM in comparison to that of the used reference standard (IC<sub>50</sub> = 38.50&#x02009;nM). The bromo isatin derivative <bold>5d</bold> showed the most potent inhibitory activity with IC<sub>50</sub> of 37.80&#x02009;nM comparable to that of staurosporine. Compounds <bold>5&#x02009;b</bold>, <bold>5c</bold> and <bold>5f</bold> showed two-digit nanomolar inhibitory activity with IC<sub>50</sub> of 52.50, 85.40 and 52.80, respectively (<xref rid="t0002" ref-type="table">Table 2</xref>).</p><p>On GSK-3&#x003b2;, the tested compounds showed potent sub-micromolar inhibitory activity as well with IC<sub>50</sub> range of 32.09&#x02013;212.30&#x02009;nM in comparison to the used reference standard (IC<sub>50</sub> = 43.38&#x02009;nM). The bromo isatin <bold>5d</bold> and the methoxy isatin <bold>5f</bold> derivative showed more potent inhibitory activity than that of staurosporine (IC<sub>50</sub> of 32.09 and 40.13&#x02009;nM, respectively). Compounds <bold>5e</bold> and <bold>5&#x02009;g</bold> showed two-digit nanomolar inhibitory activity with IC<sub>50</sub> of 75.54 and 80.75&#x02009;nM, respectively (<xref rid="t0002" ref-type="table">Table 2</xref>).</p><p>These results indicate the superiority of the bromo isatin <bold>5d</bold> and the methoxy isatin <bold>5f</bold> derivatives on both kinases (<xref rid="t0002" ref-type="table">Table 2</xref>). The methyl isatin derivative <bold>5e</bold> shows a relatively less kinase inhibitory activity than its bromo <bold>5d</bold> and methoxy <bold>5f</bold> congeners on both kinases despite of its obvious potent cellular cytotoxicity which could be attributed to its probable further cytotoxic mechanisms besides CDK2/GSK-3&#x003b2; dual inhibition.</p></sec><sec id="S0002-S2002-S3003" disp-level="3"><label>2.2.3.</label><title>Cell cycle analysis</title><p>Cyclin E/CDK2 complexation plays an important role at G1 phase, whereas, cyclin A/CDK2 complexation terminates S phase and drives the cell cycle through normal G2/M phase progression<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref><sup>,</sup><xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="CIT0103" ref-type="bibr"><sup>103</sup></xref><sup>,</sup><xref rid="CIT0104" ref-type="bibr"><sup>104</sup></xref>. Furthermore, a significant percentage of CDK2-deficient cells arrest in the G2/M phase, additionally, breast cancer cells exposed to CDK2 inhibitors show G2/M phase arrest<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="CIT0105" ref-type="bibr"><sup>105</sup></xref>. In the same vein, GSK-3&#x003b2; regulates the strength of the mitotic checkpoint and connects the PI3K and WNT-signalling pathways to mitosis, furthermore, GSK-3&#x003b2; inhibitors induce G2/M phase arrest as well<xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="CIT0106" ref-type="bibr"><sup>106</sup></xref><sup>,</sup><xref rid="CIT0107" ref-type="bibr"><sup>107</sup></xref>.</p><p>Compounds showing promising antiproliferative as well as kinase inhibitory activity <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold> were further investigated for their influence on the cell cycle progression by flow cytometry analysis using propidium iodide (PI) stain. Cell cycle parameters were compared for the breast cancer MCF-7 cells with DMSO as control and after treatment with the compounds of interest and incubation for 24&#x02009;h, and the results were presented in <xref ref-type="fig" rid="F0005">Figure 5</xref> and <xref rid="t0003" ref-type="table">Table 3</xref>.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Effect of hybrids <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold> on the phases of cell cycle of MCF-7 cells.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1862101_F0005_B"/></fig><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Effect of compounds <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold> on the phases of cell cycle of MCF-7 cells</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Comp.</th><th align="center">%G0-G1</th><th align="center">%S</th><th align="center">%G2/M</th><th align="center">%Sub-G1</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5d</bold></td><td align="left">33.97</td><td align="left">22.5</td><td align="left">30.26</td><td align="char" char=".">13.27</td></tr><tr><td align="left"><bold>5e</bold></td><td align="left">29.85</td><td align="left">23.21</td><td align="left">29.21</td><td align="char" char=".">17.73</td></tr><tr><td align="left"><bold>5f</bold></td><td align="left">22.28</td><td align="left">17.88</td><td align="left">37.82</td><td align="char" char=".">22.02</td></tr><tr><td align="left"><bold>Control</bold></td><td align="left">53.59</td><td align="left">33.82</td><td align="left">11.3</td><td align="char" char=".">1.29</td></tr></tbody></table></table-wrap><p>From the obtained results <xref ref-type="fig" rid="F0005">Figure 5</xref> and <xref rid="t0003" ref-type="table">Table 3</xref>, it is noticeable that there is an increase in the percent of cell distribution in the G2/M phase, from 11.30% in control to 30.26, 29.21 and 37.82% in treated cells with <bold>5d</bold>, <bold>5e</bold> and, <bold>5f</bold>, respectively, indicating a G2/M phase arrest which is the expected consequence from CDK2/GSK-3&#x003b2; dual inhibition confirming the mechanism of action of the designed compounds on the target kinases. Furthermore, an increase in the percent of cells accumulated in the sub-G1 phase, from 1.29% in the control to 13.27, 17.73 and 22.02% in the treated cells with <bold>5d</bold>, <bold>5e</bold> and, <bold>5f</bold>, respectively, as a result of cell apoptosis.</p><p>The high efficacy of compound <bold>5f</bold> in cell arrest at G2/M phase and in cell apoptosis as indicated by its results in <xref rid="t0003" ref-type="table">Table 3</xref> relative to its congeners <bold>5d</bold> and <bold>5e</bold> aligns with its potent effect on MCF-7 as indicated by its IC<sub>50</sub> (2.27&#x02009;&#x003bc;M) in comparison to the IC<sub>50</sub> of compounds <bold>5d</bold> and <bold>5e</bold> (3.41 and 3.45&#x02009;&#x003bc;M, respectively).</p></sec><sec id="S0002-S2002-S3004" disp-level="3"><label>2.2.4.</label><title>Apoptosis assay</title><p>To investigate further the effect of the promising compounds <bold>5d</bold>, <bold>5e</bold>, and <bold>5f</bold> on cell apoptosis, Annexin V-FITC/propidium iodide dual staining assay was performed according to the reported method<xref rid="CIT0108" ref-type="bibr"><sup>108</sup></xref>. The morphological markers of apoptosis in the breast cancer MCF-7 cell line were examined before and after treatment with the compounds of interest. Apoptosis assay depends on the translocation of the phosphatidylserine (PS) phospholipid to the cell surface in cells undergoing apoptosis which can be easily detected by staining with the fluorescent conjugate of annexin V followed by flow cytometry analysis. Simultaneously, MCF-7 cells were stained with propidium iodide (PI) which could enter cells with damaged plasma membranes only. This enables the discrimination between early apoptotic cells (positive for PS, but negative for PI) from late apoptotic and necrotic cells (positive for both PS and PI).</p><p><xref ref-type="fig" rid="F0006">Figure 6</xref> and <xref rid="t0004" ref-type="table">Table 4</xref> show that the percentage of the total apoptotic cells in MCF-7 cell line increases after treatment with compounds <bold>5d</bold>, <bold>5e</bold>, and <bold>5f</bold> (13.75, 19.74, and 26.10%, respectively) relative to control cells (0.82%) which is a significant indication of the apoptotic effect of the compounds of interest. Compounds <bold>5d</bold>, <bold>5e</bold>, and <bold>5f</bold> produced an increase in the early apoptotic phase, from 0.63 to 3.61, 4.66, and 3.94, respectively, and an increase in the late apoptotic phase, from 0.19 to 10.14, 15.08, and 22.16, respectively.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Effect of <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold> on the percentage of annexin V-FITC-positive staining in MCF-7 cells. The experiments were done in triplicates. The four quadrants identified as: <bold>LL</bold>, viable; <bold>LR</bold>, early apoptotic; <bold>UR</bold>, late apoptotic; <bold>UL</bold>, necrotic.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0006_C"/></fig><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Distribution of apoptotic cells in the AnnexinV-FITC/PI dual staining assay in MCF-7 cells upon treatment with compounds <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Comp.</th><th align="center">Total (L.R % + U.R %)</th><th align="center">Early Apoptosis (Lower Right %)</th><th align="center">Late Apoptosis (Upper Right %)</th><th align="center">Necrosis</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5d</bold></td><td align="char" char=".">13.75</td><td align="char" char=".">3.61</td><td align="char" char=".">10.14</td><td align="char" char=".">1.56</td></tr><tr><td align="left"><bold>5e</bold></td><td align="char" char=".">19.74</td><td align="char" char=".">4.66</td><td align="char" char=".">15.08</td><td align="char" char=".">1.81</td></tr><tr><td align="left"><bold>5f</bold></td><td align="char" char=".">26.10</td><td align="char" char=".">3.94</td><td align="char" char=".">22.16</td><td align="char" char=".">2.14</td></tr><tr><td align="left"><bold>Control</bold></td><td align="char" char=".">0.82</td><td align="char" char=".">0.63</td><td align="char" char=".">0.19</td><td align="char" char=".">0.49</td></tr></tbody></table></table-wrap></sec><sec id="S0002-S2002-S3005" disp-level="3"><label>2.2.5.</label><title>Cytotoxicity towards non-tumorigenic cells</title><p>In order to investigate their selectivity on cancer cells, hybrids <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold>, endowed with dual growth inhibitory action against MCF-7 and T-47D cells, were assesses for their cytotoxic action towards the non-tumorigenic breast cells (MCF-10A), <italic>via</italic> the MTT assay. The obtained IC<sub>50</sub>s and the calculated mean tumour selectivity index (S.I.); IC<sub>50</sub> for MCF-10A/IC<sub>50</sub> average for (MCF-7 and T-47D) have been presented in <xref rid="t0005" ref-type="table">Table 5</xref>. The examined hybrids exerted weak cytotoxic effect (IC<sub>50</sub> = 21.66&#x02009;&#x000b1;&#x02009;1.05, 23.59&#x02009;&#x000b1;&#x02009;0.86 and 39.95&#x02009;&#x000b1;&#x02009;1.42&#x02009;&#x003bc;M, respectively, with selectivity indexes equal 6.0, 5.9 and 7.9, respectively, <xref rid="t0005" ref-type="table">Table 5</xref>.</p><table-wrap id="t0005" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Cytotoxic action for hybrids <bold>5d</bold>, <bold>5e</bold> and <bold>5f</bold> towards non-tumorigenic breast cell line (MCF-10A), and mean tumour selectivity index (S.I.) (MCF-10A/MCF-7 and T-47D).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th rowspan="2" align="left">Comp.</th><th colspan="3" align="center">IC<sub>50</sub> (&#x000b5;M)<hr/></th><th rowspan="2" align="center">Mean tumour selectivity</th></tr><tr><th align="center">MCF-10A</th><th align="center">MCF-7</th><th align="center">T-47D</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>5d</bold></td><td align="left">21.66&#x02009;&#x000b1;&#x02009;1.05</td><td align="left">3.41&#x02009;&#x000b1;&#x02009;0.10</td><td align="left">3.82&#x02009;&#x000b1;&#x02009;0.12</td><td align="char" char=".">6.0</td></tr><tr><td align="left"><bold>5e</bold></td><td align="left">23.59&#x02009;&#x000b1;&#x02009;0.86</td><td align="left">3.45&#x02009;&#x000b1;&#x02009;0.10</td><td align="left">4.53&#x02009;&#x000b1;&#x02009;0.14</td><td align="char" char=".">5.9</td></tr><tr><td align="left"><bold>5f</bold></td><td align="left">39.95&#x02009;&#x000b1;&#x02009;1.42</td><td align="left">2.27&#x02009;&#x000b1;&#x02009;0.06</td><td align="left">7.80&#x02009;&#x000b1;&#x02009;0.25</td><td align="char" char=".">7.9</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Molecular docking study and structure activity relationship</title><p>In the present molecular docking study, a pair of protein structures were used for CDK2 and GSK-3&#x003b2;, <italic>viz</italic>, PDB ID: 1FVT<xref rid="CIT0109" ref-type="bibr"><sup>109</sup></xref> and PDB ID: 1Q41<xref rid="CIT0110" ref-type="bibr"><sup>110</sup></xref>, respectively, which are co-crystallized with potent CDK2 and GSK-3&#x003b2; oxindole-based inhibitors, respectively. Molecular docking was carried out to investigate the interaction of the designed hybrid compounds with CDK2 and GSK-3&#x003b2; kinase domain to rationalise their biological activity, to reveal their probable binding pattern and to elicit their SAR.</p><p>Initially, self-docking of the co-crystallized ligands in CDK2 and GSK-3&#x003b2; active sites was performed to validate the used molecular docking protocol. The self-docking step stimulated the binding pattern of the co-crystallized ligands accurately indicating the suitability of the used docking setup for the planned simulations. This was demonstrated by the small RMSD between the docked and the co-crystallized ligand poses in CDK2 (0.894&#x02009;&#x000c5;) and GSK-3&#x003b2; (0.471&#x02009;&#x000c5;), and by the ability of the attained docking poses to simulate the main interactions achieved by the co-crystallized ligands with the key amino acids in CDK2 and GSK-3&#x003b2; active sites (<xref ref-type="fig" rid="F0007">Figures 7</xref> and <xref rid="CIT0008" ref-type="bibr">8</xref>, respectively).</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>(<bold>A</bold>) 2&#x02009;D interaction diagram showing the oxindole derivative docking pose interactions with the key amino acids (hot spots) in the CDK2 active site. (Distances in &#x000c5;) (<bold>B</bold>) 3&#x02009;D representations of the superimposition of the docking pose (green) and the co-crystallized pose (red) of the oxindole derivative in the CDK2 active site, respectively, with RMSD of 0.894&#x02009;&#x000c5;.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0007_C"/></fig><p>In the CDK2 active site the docking pose of the oxindole derivative reproduced the key interactions of the co-crystalized ligand with the active site; it interacts in the hinge region through hydrogen bonding with Glu81 backbone CO and Leu83 backbone NH and CO. Furthermore, its sulfonamidophenylhydrazone group projected outward towards the bulk solvent with the sulphonamide group interacting with Asp86 backbone NH and side-chain carboxyl group and Lys89 side chain NH<sub>3</sub><sup>+</sup> (<xref ref-type="fig" rid="F0007">Figure 7</xref>).</p><p>As for GSK-3&#x003b2;, the docking pose of indirubin-3&#x02032;-monoxime reproduced the key interactions of the co-crystalized ligand with the active site; it interacts in the hinge region through hydrogen bonding with Asp133 backbone CO and Val135 backbone NH and CO (<xref ref-type="fig" rid="F0008">Figure 8</xref>). Furthermore, through a water mediated hydrogen bonding network, it interacts with Gln185 and Thr138 by its oxime group which is responsible for its selectivity towards GSK-3&#x003b2; over CDK2.</p><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>(<bold>A</bold>) 2&#x02009;D interaction diagram showing Indirubin-3'-monoxime docking pose interactions with the key amino acids (hot spots) in the GSK-3&#x003b2; active site. (Distances in &#x000c5;) (<bold>B</bold>) 3&#x02009;D representations of the superimposition of the docking pose (green) and the co-crystallized pose (red) of Indirubin-3'-monoxime in the GSK-3&#x003b2; active site, respectively, with RMSD of 0.471&#x02009;&#x000c5;.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0008_C"/></fig><p>In series <bold>5</bold>, the newly synthesised <italic>N<sup>1</sup></italic>-unsubstituted oxindole hybrids showed comparable binding patterns in both kinases (<xref ref-type="fig" rid="F0009">Figures 9</xref> and <xref ref-type="fig" rid="F0010">10</xref> and for further details, see supporting materials). The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding by its NH and CO with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2, and Asp133 and Val135, respectively, in GSK-3&#x003b2;.</p><fig id="F0009" orientation="portrait" position="float"><label>Figure 9.</label><caption><p>2&#x02009;D diagram (<bold>A</bold>) and 3&#x02009;D representation (<bold>B</bold>) of compound <bold>5f</bold> showing its interaction with the CDK2 active site.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0009_C"/></fig><fig id="F0010" orientation="portrait" position="float"><label>Figure 10.</label><caption><p>2&#x02009;D diagram (<bold>A</bold>) and 3&#x02009;D representation (<bold>B</bold>) of compound <bold>5f</bold> showing its interaction with the GSK-3&#x003b2; active site.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1862101_F0010_C"/></fig><p>Moreover, through hydrophobic interaction the fused phenyl ring of the oxindole nucleus interacts with the hydrophobic side chains of the surrounding amino acids; Val18, Ala31, Val64, Phe80, Leu134, and Ala144 in CDK2 and Val70, Ala83, Val110, Leu132, Leu188, and Cys199 in GSK-3&#x003b2; (<xref ref-type="fig" rid="F0009">Figures 9</xref> and <xref ref-type="fig" rid="F0010">10</xref> and for further details, see supporting materials). Therefore, increasing the substituent hydrophobicity on the oxindole nucleus enhances the binding affinity which is well reflected in the docking binding score and further in the biological activity (Br, <bold>5d</bold> &#x0003e; Cl, <bold>5c</bold> &#x02248; CH<sub>3</sub>, <bold>5e</bold> &#x0003e; F, <bold>5&#x02009;b</bold>) (<xref rid="t0001 t0002 t0006" ref-type="table">Tables 1, 2 and 6</xref>). The remarkable binding affinity of the relatively polar methoxy group (OCH<sub>3</sub>, <bold>5f</bold>) is attributed to the fact that it is directed towards the bulk solvent and so decreased the solvation penalty during the binding scenario resulting in a considerable increase in the binding affinity. On the other hand, despite of its relatively higher hydrophobicity, the dimethyl substituted hybrid <bold>5&#x02009;g</bold> does not show significant predicted binding score or experimental biological activity what could be attributed to the C<sup>7</sup> methyl substituent which sterically clashes with the bottom of the hinge region hindering the key interaction of the NH and CO of the oxindole ring with the key amino acids; Glu81 and Leu83 in CDK2, respectively, and Asp133 and Val135 in GSK-3&#x003b2;, respectively (For further details, see supporting materials).</p><table-wrap id="t0006" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Docking energy scores (<italic>S</italic>) in kcal/mol for the newly synthesised hybrid compounds and the co-crystalized compounds in CDK2 and GSK-3&#x003b2; kinase domain</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="80pt"/><col width="80pt"/><col width="80pt"/></colgroup><thead><tr><th align="left">Compound</th><th align="center">Energy score (S) kcal/mol CDK2</th><th align="center">Energy score (S) kcal/mol GSK-3&#x003b2;</th></tr></thead><tbody valign="top"><tr><td align="left">5a</td><td align="char" char=".">&#x02212;9.53</td><td align="char" char=".">&#x02212;9.99</td></tr><tr><td align="left">5b</td><td align="char" char=".">&#x02212;9.89</td><td align="char" char=".">&#x02212;10.40</td></tr><tr><td align="left">5c</td><td align="char" char=".">&#x02212;10.07</td><td align="char" char=".">&#x02212;10.59</td></tr><tr><td align="left">5d</td><td align="char" char=".">&#x02212;10.22</td><td align="char" char=".">&#x02212;10.81</td></tr><tr><td align="left">5e</td><td align="char" char=".">&#x02212;10.05</td><td align="char" char=".">&#x02212;10.53</td></tr><tr><td align="left">5f</td><td align="char" char=".">&#x02212;10.35</td><td align="char" char=".">&#x02212;10.96</td></tr><tr><td align="left">5g</td><td align="char" char=".">&#x02212;10.39</td><td align="char" char=".">&#x02212;10.60</td></tr><tr><td align="left">7a</td><td align="char" char=".">&#x02212;9.19</td><td align="char" char=".">&#x02212;10.40</td></tr><tr><td align="left">7b</td><td align="char" char=".">&#x02212;9.61</td><td align="char" char=".">&#x02212;10.24</td></tr><tr><td align="left">7c</td><td align="char" char=".">&#x02212;10.03</td><td align="char" char=".">&#x02212;11.48</td></tr><tr><td align="left">7d</td><td align="char" char=".">&#x02212;10.21</td><td align="char" char=".">&#x02212;11.76</td></tr><tr><td align="left">7e</td><td align="char" char=".">&#x02212;9.98</td><td align="char" char=".">&#x02212;11.58</td></tr><tr><td align="left">7f</td><td align="char" char=".">&#x02212;10.05</td><td align="char" char=".">&#x02212;10.68</td></tr><tr><td align="left">7g</td><td align="char" char=".">&#x02212;10.56</td><td align="char" char=".">&#x02212;11.27</td></tr><tr><td align="left">7h</td><td align="char" char=".">&#x02212;10.40</td><td align="char" char=".">&#x02212;11.46</td></tr><tr><td align="left">13a</td><td align="char" char=".">&#x02212;13.60</td><td align="char" char=".">&#x02212;11.77</td></tr><tr><td align="left">13b</td><td align="char" char=".">&#x02212;14.72</td><td align="char" char=".">&#x02212;11.92</td></tr><tr><td align="left">Co-crystalized ligand</td><td align="char" char=".">&#x02212;10.63</td><td align="char" char=".">&#x02212;12.00</td></tr></tbody></table></table-wrap><p>The hydrazono linker NH interacts through hydrogen bonding with the backbone CO of Leu83 and Val135 in CDK2 and GSK-3&#x003b2;, respectively, projecting the benzofuran moiety outward towards the bulk solvent which is involved in a hydrophobic interaction with the hydrophobic side chains of the surrounding amino acids lining the gate of the hinge region; Ile10, Phe82, and Leu298 in CDK2 and Ile62, Tyr134 and Pro136 in GSK-3&#x003b2; (<xref ref-type="fig" rid="F0009">Figures 9</xref> and <xref ref-type="fig" rid="F0010">10</xref> and for further details, see supporting materials).</p><p>In series <bold>7</bold> and <bold>13</bold>, the <italic>N<sup>1</sup></italic>-substitutions on the oxindole nucleus hinder the compounds from achieving the key interactions with hinge region amino acids; Glu81 and Leu83 in CDK2, and Asp133 and Val135 in GSK-3&#x003b2; what rationalises their moderate to low antiproliferative activity (For further details, see supporting materials). Molecular docking simulations show their non-selective bindings and random binding patterns what rationalise their low activity despite of their good docking binding scores (<xref rid="t0006" ref-type="table">Table 6</xref>).</p><p>These results point out the criticality of N<sup>1</sup> being unsubstituted for CDK2/GSK-3&#x003b2; kinase inhibition. The N<sup>1</sup>-benzyloxindole derivative <bold>7&#x02009;h</bold> showing promising antiproliferative activity might be exerting its effect through other mechanism than CDK2/GSK-3&#x003b2; kinase inhibition.</p></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Conclusions</title><p>In the present study three series of oxindole-benzofuran hybrids were designed and synthesised as dual CDK2/GSK-3&#x003b2; inhibitors targeting breast cancer (<bold>5a-g</bold>, <bold>7a-h</bold>, and <bold>13a-b</bold>). In MTT assay on the breast cancer cell lines MCF-7 and T-47D, the <italic>N<sup>1</sup></italic>-unsubstituted oxindole derivatives, <bold>series 5</bold>, showed moderate to potent activity on both breast cancer cell lines. Compounds <bold>5d-f</bold> showed the most potent cytotoxic activity with IC<sub>50</sub> of 3.41, 3.45 and 2.27&#x02009;&#x003bc;M, respectively, on MCF-7 and IC<sub>50</sub> of 3.82, 4.53 and 7.80&#x02009;&#x003bc;M, respectively, on T-47D cell lines, in comparison to the used reference standard (staurosporine) IC<sub>50</sub> of 4.81 and 4.34&#x02009;&#x003bc;M, respectively. On the other hand, the <italic>N<sup>1</sup></italic>-substituted oxindole derivatives, <bold>series 7 and 13</bold>, showed moderate to weak cytotoxic activity on both breast cancer cell lines except for compound <bold>7&#x02009;h</bold> which showed potent antiproliferative activity with IC<sub>50</sub> of 4.32 and 1.72&#x02009;&#x003bc;M on MCF-7 and T-47D cell lines, respectively. CDK2 and GSK-3&#x003b2; inhibition testing of the potent <bold>series 5</bold> indicated that compounds <bold>5d</bold> and <bold>5f</bold> exhibit potent dual CDK2/GSK-3&#x003b2; inhibitory activity with IC<sub>50</sub> of 37.77 and 52.75&#x02009;nM, respectively, on CDK2 and 32.09 and 40.13&#x02009;nM, respectively, on GSK-3&#x003b2;. The most potent hybrids <bold>5d-f</bold> triggered cell cycle arrest in the G2/M phase as a consequence of their dual CDK2/GSK-3&#x003b2; inhibition. Moreover, compounds <bold>5d-f</bold> induced apoptosis in MCF-7 cells as indicated by the percent of the total apoptosis of 13.75, 19.74, and 26.10%, respectively, in comparison to the untreated cells which showed 0.82% total apoptosis. The molecular docking study showed that the newly synthesised <italic>N<sup>1</sup></italic>-unsubstituted oxindole hybrids have comparable binding patterns in both CDK2 and GSK-3&#x003b2;. The oxindole ring is accommodated in the hinge region interacting through hydrogen bonding with the backbone CO and NH of the key amino acids Glu81 and Leu83, respectively, in CDK2 and Asp133 and Val135, respectively, in GSK-3&#x003b2;. Moreover, through hydrophobic interaction the fused phenyl ring of the oxindole nucleus interacts with the hydrophobic side chains of the surrounding amino acids; Val18, Ala31, Val64, Phe80, Leu134, and Ala144 in CDK2 and Val70, Ala83, Val110, Leu132, Leu188, and Cys199 in GSK-3&#x003b2;. The hydrazono linker NH interacts through hydrogen bonding with the backbone CO of Leu83 and Val135 in CDK2 and GSK-3&#x003b2;, respectively, projecting the benzofuran moiety outward towards the bulk solvent which is involved in a hydrophobic interaction with the hydrophobic side chains of the surrounding amino acids lining the gate of the hinge region; Ile10, Phe82, and Leu298 in CDK2 and Ile62, Tyr134 and Pro136 in GSK-3&#x003b2;. In series <bold>7</bold> and <bold>13</bold>, the <italic>N<sup>1</sup></italic>-substitutions on the oxindole nucleus hinder the compounds from achieving the key interactions with hinge region amino acids; Glu81 and Leu83 in CDK2, and Asp133 and Val135 in GSK-3&#x003b2; what rationalises their moderate to low antiproliferative activity.</p></sec><sec id="S0005" disp-level="1"><label>5.</label><title>Experimental</title><sec id="S0005-S2001" disp-level="2"><label>5.1.</label><title>Chemistry</title><sec id="S0005-S2001-S3001" disp-level="3"><label>5.1.1.</label><title>General</title><p>Melting points were measured with a Stuart melting point apparatus and were uncorrected. Infra-red spectra were recorded on Schimadzu FT-IR 8400S spectrophotometer. The NMR spectra were recorded by Bruker spectrometer at 400&#x02009;MHz. <sup>13&#x02009;</sup>C NMR spectra were run at 100&#x02009;MHz in deuterated dimethylsulphoxide (DMSO<italic>d6</italic>). Elemental analyses were carried out at the Regional Centre for Microbiology and Biotechnology, Al-Azhar University, Cairo, Egypt. Unless otherwise noted, all solvents and reagents were commercially available and used without further purification. Compounds (<bold>2</bold> and <bold>3</bold>)<xref rid="CIT0097" ref-type="bibr"><sup>97</sup></xref>, (<bold>6a&#x02013;h</bold>)<xref rid="CIT0111" ref-type="bibr"><sup>111&#x02013;112</sup></xref>, (<bold>8&#x02013;9</bold>)<xref rid="CIT0113" ref-type="bibr"><sup>113</sup></xref>, and (<bold>12&#x02009;b</bold>)<xref rid="CIT0114" ref-type="bibr"><sup>114</sup></xref> were prepared according to the reported methods.</p><sec id="S0005-S2001-S3001-S4001" disp-level="4"><label>5.1.1.2.</label><title>Synthesis of 5-bromobenzofuran-2-carbohydrazide 3</title><p>To hot stirred solution of ethyl 5-bromobenzofuran-2-carboxylate <bold>2</bold> (1&#x02009;g, 3.7&#x02009;mmol) in 30&#x02009;ml of methanol, hydrazine hydrate (0.25&#x02009;ml, 7.5&#x02009;mmol) was added. The reaction solution was left for heating under reflux for 4&#x02009;h, and then poured onto cold water. The formed solid was collected by filtration, washed with diethyl ether and recrystallized from EtOH/DMF mixture to furnish the key intermediate <bold>3</bold>.</p></sec><sec id="S0005-S2001-S3001-S4002" disp-level="4"><label>5.1.1.3.</label><title>Synthesis of target compounds 5a&#x02013;g and 7a&#x02013;h</title><p>5-Bromobenzofuran-2-carbohydrazide <bold>3</bold> (0.3&#x02009;g, 1.2&#x02009;mmol) was added to a hot solution of equivalent amount of the appropriate isatin derivative (<bold>4a&#x02013;g</bold> or <bold>6a&#x02013;h</bold>) in ethanol (15&#x02009;ml) with catalytic amount of ethanoic acid. The reaction mixture was heated under reflux for 4&#x02013;7&#x02009;h with TLC monitoring, once the reaction completed, the reaction mixture was left for cooling then was filtered-off. The produced solid was washed with water, diethyl ether and recrystallized from dioxane/propanol mixture to produce target compounds <bold>5a&#x02013;g</bold> and <bold>7a&#x02013;h</bold>, respectively.</p><sec id="S0005-S2001-S3001-S4002-S5001" disp-level="5"><label>5.1.1.3.1.</label><title>5-Bromo-N'-(2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5a</title><p>Yellow powder (yield 75%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 6.94&#x02013;7.00 (m, 1H, Ar-H), 7.11 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.41&#x02013;7.47 (m, 1H, Ar-H), 7.64&#x02013;7.84 (m, 3H, Ar-H), 7.99 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.09, 8.11 (2&#x02009;s, 1H, Ar-H), 10.91, 11.39 (2&#x02009;s, 1H, NH indolin-2-one), 11.89, 14.06 (2&#x02009;s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 111.32, 114.73, 116.72, 120.10, 121.76, 122.45, 123.30, 126.13, 127.23, 129.61, 131.18, 132.70, 133.70, 143.29, 153.87, 163.35 (C&#x02009;=&#x02009;O indolin-2-one), 165.04 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3380, 3345 (2NH) and 1711, 1701 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 384 [M<sup>+</sup>+2, 50.94], 382 [M<sup>+</sup>, 48.60], 160 [100]; Analysis calculated for C<sub>17</sub>H<sub>10</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 53.15; H, 2.62; N, 10.94; found C, 53.33; H, 2.64; N, 10.82.</p></sec><sec id="S0005-S2001-S3001-S4002-S5002" disp-level="5"><label>5.1.1.3.2.</label><title>5-Bromo-N'-(5-fluoro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5b</title><p>Red powder (yield 77%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 6.92&#x02013;7.00 (m, 1H, Ar-H), 7.24&#x02013;7.33 (m, 1H, Ar-H), 7.49, 7.86 (2br s, 1H, Ar-H), 7.67&#x02013;7.71 (m, 1H, Ar-H), 7.74 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.96 (d, 0.6H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 8.04&#x02013;8.13 (m, 1.4H, Ar-H), 10.92,11.42 (2&#x02009;s, 1H, NH indolin-2-one), 12.02, 14.02 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3280, 3245 (2NH) and 1723, 1705 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>BrFN<sub>3</sub>O<sub>3</sub>: C, 50.77; H, 2.26; N, 10.45; found C, 50.90; H, 2.24; N, 10.57.</p></sec><sec id="S0005-S2001-S3001-S4002-S5003" disp-level="5"><label>5.1.1.3.3.</label><title>5-Bromo-N'-(5-chloro-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5c</title><p>Orange powder (yield 83%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 6.94&#x02013;7.01 (m, 1H, Ar-H), 7.45&#x02013;7.50 (m, 1H, Ar-H), 7.64&#x02013;7.76 (m, 2.3H, Ar-H), 8.04, 8.10 (2&#x02009;s, 1H, Ar-H), 8.14&#x02013;8.17 (m, 1.7H, Ar-H), 11.03,11.50 (2&#x02009;s, 1H, NH indolin-2-one), 12.08, 13.96 (2&#x02009;s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 112.66, 114.60, 116.94, 118.92, 121.28, 124.34, 126.29, 126.77, 131.04, 132.93, 137.31, 141.43, 143.41, 153.82, 163.17 (C&#x02009;=&#x02009;O indolin-2-one), 164.88 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3300, 3240 (2NH) and 1735, 1702 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>BrClN<sub>3</sub>O<sub>3</sub>: C, 48.77; H, 2.17; N, 10.04; found C, 48.82; H, 2.16; N, 9.93.</p></sec><sec id="S0005-S2001-S3001-S4002-S5004" disp-level="5"><label>5.1.1.3.4.</label><title>5-Bromo-N'-(5-bromo-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5d</title><p>Orange powder (yield 87%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 6.91&#x02013;6.97 (m, 1H, Ar-H), 7.60 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.71&#x02013;7.76 (m, 2H, Ar-H), 8.03&#x02013;8.15 (m, 2H, Ar-H), 8.31 (s, 1H, Ar-H), 11.05,11.52 (2&#x02009;s, 1H, NH indolin-2-one), 12.09, 13.99 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3295, 3271 (2NH) and 1732, 1701 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>17</sub>H<sub>9</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>: C, 44.09; H, 1.96; N, 9.07; found C, 43.81; H, 1.98; N, 9.16.</p></sec><sec id="S0005-S2001-S3001-S4002-S5005" disp-level="5"><label>5.1.1.3.5.</label><title>5-Bromo-N'-(5-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5e</title><p>Brown powder (yield 84%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 2.23, 2.35 (2&#x02009;s, 3H, CH<sub>3</sub>), 6.84&#x02013;6.88 (m, 1H, Ar-H), 7.22&#x02013;7.27 (m, 1H, Ar-H), 7.47 (s, 0.6H, Ar-H), 7.68&#x02013;7.71 (m, 1H, Ar-H), 7.74&#x02013;7.79 (m, 1H, Ar-H), 7.82&#x02013;7.88 (m, 1H, Ar-H), 8.00 (s, 0.4H, Ar-H), 8.09&#x02013;8.14 (m, 1H, Ar-H), 10.80, 11.28 (2&#x02009;s, 1H, NH indolin-2-one), 11.83, 14.05 (2&#x02009;s, 1H, NH) ; <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 20.97 (CH<sub>3</sub>), 111.57, 114.65, 116.89, 120.09, 122.08, 126.14, 127.54, 129.60, 130.92, 131.15, 132.44, 133.12, 141.02, 142.44, 153.84, 163.41 (C&#x02009;=&#x02009;O indolin-2-one), 165.09 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3320, 3341 (2NH) and 1721, 1700 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 54.29; H, 3.04; N, 10.55; found C, 54.57; H, 3.01; N, 10.62.</p></sec><sec id="S0005-S2001-S3001-S4002-S5006" disp-level="5"><label>5.1.1.3.6.</label><title>5-Bromo-N'-(5-methoxy-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5f</title><p>Red powder (yield 82%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 3.80, 3.83 (2&#x02009;s, 3H, OCH<sub>3</sub>), 6.85&#x02013;6.91 (m, 1H, Ar-H), 6.98&#x02013;7.07 (m, 1H, Ar-H), 7.18 (s, 1H, Ar-H), 7.68&#x02013;7.76 (m, 2H, Ar-H), 7.82, 8.01 (2&#x02009;s, 1H, Ar-H), 8.08&#x02013;8.13 (m, 1H, Ar-H), 10.72,11.20 (2&#x02009;s, 1H, NH indolin-2-one), 11.97, 14.10 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3324, 3301 (2NH) and 1718, 1710 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 416 [M<sup>+</sup>+2, 75.42], 414 [M<sup>+</sup>, 77.51], 402 [100]; Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>4</sub>: C, 52.19; H, 2.92; N, 10.14; found C, 52.01; H, 2.95; N, 10.25.</p></sec><sec id="S0005-S2001-S3001-S4002-S5007" disp-level="5"><label>5.1.1.3.7.</label><title>5-Bromo-N'-(5,7-dimethyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 5&#x02009;g</title><p>Red powder (yield 76%), m.p. &#x0003e; 300&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 2.20, 20.22 (2&#x02009;s, 3H, CH<sub>3</sub> of C-7 of indolin-2-one), 2.29, 2.32 (2&#x02009;s, 3H, CH<sub>3</sub> of C-5 of indolin-2-one), 7.06, 7.11 (2&#x02009;s, 1H, Ar-H), 7.30 (s, 0.5H, Ar-H), 7.69&#x02013;7.71 (m, 1.5H, Ar-H), 7.75&#x02013;7.79 (m, 1H, Ar-H), 7.82, 8.00 (2&#x02009;s, 1H, Ar-H), 8.09, 8.11 (2&#x02009;s, 1H, Ar-H), 10.82,11.29 (2&#x02009;s, 1H, NH indolin-2-one), 11.78, 14.06 (2&#x02009;s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 16.31 (CH<sub>3</sub> C-7 of indolin-2-one), 20.88 (CH<sub>3</sub> C-5 of indolin-2-one), 114.67, 116.88, 119.47, 120.97, 123.31, 126.13, 129.61, 131.11, 132.34, 134.53, 135.97, 139.65, 141.47, 142.47, 153.84, 163.82 (C&#x02009;=&#x02009;O indolin-2-one), 165.16 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3350, 3315 (2NH) and 1723, 1701 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 414 [M<sup>+</sup>+2, 17.45], 412 [M<sup>+</sup>, 14.19], 160 [100]; Analysis calculated for C<sub>19</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 55.36; H, 3.42; N, 10.19; found C, 55.53; H, 3.38; N, 10.27.</p></sec><sec id="S0005-S2001-S3001-S4002-S5008" disp-level="5"><label>5.1.1.3.8.</label><title>5-Bromo-N'-(1-methyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7a</title><p>Yellow powder (yield 81%), m.p. 260&#x02013;262&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 3.27 (s, 3H, <italic>N</italic>-CH<sub>3</sub>), 7.19 (t, 2H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.50 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.68&#x02013;7.71 (m, 2H, Ar-H), 7.76 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.97, 14.02 (2&#x02009;s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 26.26 (<italic>N</italic>-CH<sub>3</sub>), 110.59, 114.68, 116.94, 119.40, 121.41, 123.84, 126.16, 129.60, 130.33, 131.24, 132.62, 138.18, 144.51, 151.44, 153.87, 161.58 (C&#x02009;=&#x02009;O indolin-2-one), 165.10 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3345 (NH) and 1720, 1695 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 400 [M<sup>+</sup>+2, 92.41], 398 [M<sup>+</sup>, 94.85], 91 [100]; Analysis calculated for C<sub>18</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 54.29; H, 3.04; N, 10.55; found C, 54.48; H, 3.02; N, 10.64.</p></sec><sec id="S0005-S2001-S3001-S4002-S5009" disp-level="5"><label>5.1.1.3.9.</label><title>N'-(1-Allyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7&#x02009;b</title><p>Orange powder (yield 73%), m.p. 207&#x02013;209&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 4.46 (s, 2H, <italic>N</italic>-CH<sub>2</sub>), 5.22&#x02013;5.31 (m, 2H, =CH<sub>2</sub>), 5.88&#x02013;5.97 (m, 1H, <italic>N</italic>-CH<sub>2</sub>-C<underline>H</underline>), 7.13 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.19 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.47 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.68&#x02013;7.72 (m, 2H, Ar-H), 7.76 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz),) , 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.99, 13.97 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3304 (NH) and 1715, 1701 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>20</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 56.62; H, 3.33; N, 9.90; found C, 56.77; H, 3.31; N, 10.01.</p></sec><sec id="S0005-S2001-S3001-S4002-S5010" disp-level="5"><label>5.1.1.3.10.</label><title>5-Bromo-N'-(1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7c</title><p>Yellow powder (yield 65%), m.p. 216&#x02013;218&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 0.94 (d, 6H, -CH-(C<underline>H<sub>3</sub></underline>)<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 2.09&#x02013;2.16 (m, 1H, <italic>N</italic>-CH<sub>2</sub>-C<underline>H</underline>), 3.36 (d, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.17 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.24 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.47 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.67&#x02013;7.70 (m, 2H, Ar-H), 7.77 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.84 (s, 1H, Ar-H), 8.08 (s, 1H, Ar-H), 13.99 (s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3312 (NH) and 1720, 1711 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>21</sub>H<sub>18</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 57.29; H, 4.12; N, 9.54; found C, 57.08; H, 4.17; N, 9.47.</p></sec><sec id="S0005-S2001-S3001-S4002-S5011" disp-level="5"><label>5.1.1.3.11.</label><title>Ethyl-2&#x02013;(3-(2&#x02013;(5-bromobenzofuran-2-carbonyl)hydrazono)-2-oxoindolin-1-yl)acetate 7d</title><p>Orange powder (yield 69%), m.p. 215&#x02013;216&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 1.23 (t, 3H, CH<sub>3</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 4.18 (q, 2H, CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 4.76 (s, 2H, <italic>N</italic>-CH<sub>2</sub>), 7.22 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.50 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.96&#x02013;7.78 (m, 2H, Ar-H), 7.87 (s, 1H, Ar-H), 8.10 (s, 1H, Ar-H), 13.81 (s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 14.49 (CH<sub>3</sub>), 41.47 (-<underline>C</underline>H<sub>2</sub>-CH<sub>3</sub>), 61.97 (<italic>N</italic>-CH<sub>2</sub>), 110.93, 113.40, 114.68, 116.96, 119.28, 121.62, 124.20, 124.67, 126.19, 129.59, 131.33, 132.68, 143.48, 150.87, 153.88, 161.55 (C&#x02009;=&#x02009;O indolin-2-one), 165.22 (C&#x02009;=&#x02009;O hydrazide), 167.89 (C&#x02009;=&#x02009;O ester); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3324 (NH) and 1745, 1715, 1698 (3&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>21</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>5</sub>: C, 53.63; H, 3.43; N, 8.94; found C, 53.80; H, 3.42; N, 8.88.</p></sec><sec id="S0005-S2001-S3001-S4002-S5012" disp-level="5"><label>5.1.1.3.12.</label><title>N'-(1-Benzyl-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7e</title><p>Yellow powder (yield 80%), m.p. 248&#x02013;250&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 5.01, 5.05 (2&#x02009;s, 2H, <italic>N</italic>-CH<sub>2</sub>), 7.06 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.17 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.29&#x02013; 7.32 (m, 4H, Ar-H), 7.42&#x02013;7.48 (m, 2H, Ar-H), 7.69&#x02013;7.73 (m, 1.5H, Ar-H), 7.77 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.87, 8.02 (2&#x02009;s, 1H, Ar-H), 8.09&#x02013;8.12 (m, 1.5H, Ar-H), 12.01, 13.99 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3309 (NH) and 1712, 1701 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 476 [M<sup>+</sup>+2, 16.41], 474 [M<sup>+</sup>, 21.15], 475 [100]; Analysis calculated for C<sub>24</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>3</sub>: C, 60.77; H, 3.40; N, 8.86; found C, 60.98; H, 3.38; N, 8.75.</p></sec><sec id="S0005-S2001-S3001-S4002-S5013" disp-level="5"><label>5.1.1.3.13.</label><title>5-Bromo-N'-(2-oxo-1-phenethylindolin-3-ylidene)benzofuran-2-carbohydrazide 7f</title><p>Yellow powder (yield 78%), m.p. 239&#x02013;241&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 2.99 (br s, 2H, <italic>N</italic>-CH<sub>2</sub>-C<underline>H<sub>2</sub></underline>), 4.03 (br s, 2H, <italic>N</italic>-C<underline>H<sub>2</sub></underline>-CH<sub>2</sub>), 7.16&#x02013;7.22 (m, 3H, Ar-H), 7.28&#x02013;7.32 (m, 4H, Ar-H), 7.45 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.46 (t, 2H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.78 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.85 (s, 1H, Ar-H), 8.09 (s, 1H, Ar-H), 11.97, 13.94 (2&#x02009;s, 1H, NH); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 33.43 (<italic>N</italic>-CH<sub>2</sub>-<underline>C</underline>H<sub>2</sub>), 41.36 (<italic>N</italic>-<underline>C</underline>H<sub>2</sub>-CH<sub>2</sub>), 110.86, 114.71, 116.95, 119.34, 120.21, 121.53, 123.75, 126.15, 127.02, 127.92, 128.93, 129.34, 129.59, 130.55, 131.24, 132.58, 135.38, 138.58, 141.28, 143.61, 153.87, 161.36 (C&#x02009;=&#x02009;O indolin-2-one), 165.06 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3356 (NH) and 1721, 1703 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C25H18BrN3O3: C, 61.49; H, 3.72; N, 8.60; found C, 61.63; H, 3.70; N, 8.66.</p></sec><sec id="S0005-S2001-S3001-S4002-S5014" disp-level="5"><label>5.1.1.3.14.</label><title>5-Bromo-N'-(5-bromo-1-isobutyl-2-oxoindolin-3-ylidene)benzofuran-2-carbohydrazide 7&#x02009;g</title><p>Orange powder (yield 74%), m.p. 244&#x02013;246&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 0.94 (d, 6H, &#x02013;CH&#x02013;(C<underline>H<sub>3</sub></underline>)<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz), 2.11&#x02013;2.17 (m, 1H, <italic>N</italic>-CH<sub>2</sub>-C<underline>H</underline>), 3.51 (d, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 6.94&#x02013;7.12 (m, 1H, Ar-H), 7.70 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.73&#x02013;7.80 (m, 2H, Ar-H), 8.10&#x02013;8.18 (m, 2H, Ar-H), 8.35 (s, 1H, Ar-H), 12.12, 13.98 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3358 (NH) and 1724, 1700 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C21H17Br2N3O3: C, 48.58; H, 3.30; N, 8.09; found C, 48.73; H, 3.27; N, 8.14.</p></sec><sec id="S0005-S2001-S3001-S4002-S5015" disp-level="5"><label>5.1.1.3.15.</label><title>N'-(1-Benzyl-5-bromo-2-oxoindolin-3-ylidene)-5-bromobenzofuran-2-carbohydrazide 7&#x02009;h</title><p>Yellow powder (yield 81%), m.p. 236&#x02013;237&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 5.00, 5.04 (2&#x02009;s, 2H, <italic>N</italic>-C<underline>H<sub>2</sub></underline>), 7.03 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.29&#x02013;7.32 (m, 1H, Ar-H), 7.35&#x02013;7.39 (m, 2H, Ar-H), 7.42 (d, 2H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.51&#x02013;7.61 (m, 1H, Ar-H), 7.66&#x02013;7.70 (m, 1H, Ar-H), 7.73&#x02013;7.77 (m, 2H, Ar-H), 7.87, 8.13 (2&#x02009;s, 1H, Ar-H), 8.07 (s, 1H, Ar-H), 12.19, 13.87 (2&#x02009;s, 1H, NH); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3335 (NH) and 1731, 1708 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>24</sub>H<sub>15</sub>Br<sub>2</sub>N<sub>3</sub>O<sub>3</sub>: C, 52.11; H, 2.73; N, 7.60; found C, 51.86; H, 2.74; N, 7.69.</p></sec></sec><sec id="S0005-S2001-S3001-S4003" disp-level="4"><label>5.1.1.4.</label><title>Synthesis of 5-bromo-2-isocyanatobenzofuran 11</title><p>5-Bromobenzofuran-2-carbonyl chloride <bold>9</bold> (1&#x02009;g, 3.8&#x02009;mmol) was dissolved in dry acetone (30&#x02009;ml), then added drop wisely to aqueous solution of equivalent amount of NaN<sub>3</sub> at 0&#x02009;&#x000b0;C over 30&#x02009;min. The formed precipitate was filtrated under vacuum and washed with pet. ether, then heated without purification in dry toluene for 1&#x02009;h to produce the intermediate <bold>11</bold>.</p></sec><sec id="S0005-S2001-S3001-S4004" disp-level="4"><label>5.1.1.5.</label><title>Synthesis of hydrazones 12a-b</title><p>To hot stirred solution of the appropriate indolin-2-one <bold>6c</bold> and <bold>6e</bold> (6&#x02009;mmol) in isopropyl alcohol (22&#x02009;ml), hydrazine hydrate (0.50&#x02009;ml, 15&#x02009;mmol) was added. The reaction solution was heated under reflux for 3&#x02009;h, then cold to room temperature. The formed solid was collected <italic>via</italic> filtration, washed with <italic>n</italic>-hexane and recrystallized from acetonitrile to afford the key intermediates hydrazones <bold>12a-b</bold> in a good yield (87&#x02013;92%).</p><sec id="S0005-S2001-S3001-S4004-S5001" disp-level="5"><label>5.1.1.5.1.</label><title>3-Hydrazono-1-isobutylindolin-2-one 12a</title><p>Yellow powder (yield 65%), m.p. 91&#x02013;93&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 0.98 (d, 6H, -CH-(C<underline>H<sub>3</sub></underline>)<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz), 2.02&#x02013;2.12 (m, 1H, <italic>N</italic>-CH<sub>2</sub>-C<underline>H</underline>), 3.55 (d, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz), 7.02 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz), 7.08 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.21 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.41 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz), 9.67 (d, 1H, NH<sub>2</sub>, D<sub>2</sub>O exchangeable, <italic>J</italic>&#x02009;=&#x02009;14.8&#x02009;Hz), 10.54 (d, 1H, NH<sub>2</sub>, D<sub>2</sub>O exchangeable, <italic>J</italic>&#x02009;=&#x02009;14.8&#x02009;Hz); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 20.45 (&#x02013;CH&#x02013;(<underline>C</underline>H<sub>3</sub>)<sub>2</sub>), 27.39 (<italic>N&#x02013;</italic>CH<sub>2</sub>&#x02013;<underline>C</underline>H), 46.40 (<italic>N&#x02013;</italic>CH<sub>2</sub>), 109.59, 117.73, 121.83, 122.23, 125.66, 127.45, 140.07, 161.49 (C&#x02009;=&#x02009;O indolin-2-one); Analysis calculated for C<sub>12</sub>H<sub>15</sub>N<sub>3</sub>O: C, 66.34; H, 6.96; N, 19.34; found C, 66.53; H, 6.91; N, 19.39.</p></sec></sec><sec id="S0005-S2001-S3001-S4005" disp-level="4"><label>5.1.1.6.</label><title>Synthesis of target compounds 13a-b</title><p>To the previously prepared solution of isocyanate <bold>11</bold>, equimolar amount of hydrazone <bold>12a&#x02013;b</bold> was added. The reaction mixture was heated for 4&#x02009;h, the formed precipitate was filtrated while hot, washed with diethyl ether and recrystallized from DMF/EtOH mixture to produce targeted compounds <bold>13a&#x02013;b</bold>, respectively.</p><sec id="S0005-S2001-S3001-S4005-S5001" disp-level="5"><label>5.1.1.6.1.</label><title>N-(5-Bromobenzofuran-2-yl)-2&#x02013;(1-isobutyl-2-oxoindolin-3-ylidene)hydrazine-1-carboxamide 13a</title><p>Yellow powder (yield 73%), m.p. 208&#x02013;210&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 0.94 (d, 6H, &#x02013;CH&#x02013;(C<underline>H<sub>3</sub></underline>)<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 2.06&#x02013;2.13 (m, 1H, <italic>N</italic><bold>&#x02013;</bold>CH<sub>2</sub><bold>&#x02013;</bold>C<underline>H</underline>), 3.57 (d, 2H, <italic>N</italic>-CH<sub>2</sub>, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz), 6.55 (s, 1H, Ar-H), 6.63 (s, 0.5H, Ar-H), 7.15&#x02013;7.21 (m, 1H, Ar-H), 7.28&#x02013;7.32 (m, 1.5H, Ar-H), 7.41&#x02013;7.47 (m, 2H, Ar-H), 7.70&#x02013;7.74 (m, 2H, Ar-H), 10.12 (s, 1H, NH urea), 11.33 (s, 1H, NH urea); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 20.44 (&#x02013;CH&#x02013;(<underline>C</underline>H<sub>3</sub>)<sub>2</sub>), 27.28 (<italic>N&#x02013;</italic>CH<sub>2</sub>&#x02013;<underline>C</underline>H), 66.82 (<italic>N</italic>&#x02013;CH<sub>2</sub>), 110.60, 112.52, 116.02, 119.90, 121.04, 122.52, 123.30, 125.07, 131.39, 132.27, 133.49, 143.34, 148.57, 148.99, 150.31, 151.01, 161.27 (C&#x02009;=&#x02009;O indolin-2-one), 165.09 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3345, 3240 (2NH) and 1730, 1711 (2&#x02009;C&#x02009;=&#x02009;O); MS <italic>m/z</italic> [%]: 457 [M<sup>+</sup>+2, 27.45], 455 [M<sup>+</sup>, 29.72], 414 [100]; Analysis calculated for C<sub>21</sub>H<sub>19</sub>BrN<sub>4</sub>O<sub>3</sub>: C, 55.40; H, 4.21; N, 12.31; found C, 55.59; H, 4.16; N, 12.42.</p></sec><sec id="S0005-S2001-S3001-S4005-S5002" disp-level="5"><label>5.1.1.6.2.</label><title>2&#x02013;(1-Benzyl-2-oxoindolin-3-ylidene)-N-(5-bromobenzofuran-2-yl)hydrazine-1-carboxamide 13&#x02009;b</title><p>Yellow powder (yield 68%), m.p. 217&#x02013;219&#x02009;&#x000b0;C; <sup>1</sup>H NMR <italic>ppm</italic>: 4.98 (s, 2H, <italic>N</italic>-CH<sub>2</sub>), 6.53 (s, 1H, Ar-H), 6.61 (s, 1H, Ar-H), 7.02 (d, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.11 (t, 1H, Ar-H, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz), 7.25&#x02013;7.30 (m, 2H, Ar-H), 7.31&#x02013;7.38 (m, 3H, Ar-H), 7.41&#x02013;7.45 (m, 2H, Ar-H), 7.68&#x02013;7.71 (m, 2H, Ar-H), 10.10 (s, 1H, NH urea), 11.38 (s, 1H, NH urea); <sup>13&#x02009;</sup>C NMR <italic>&#x003b4; ppm</italic>: 42.51 (CH<sub>2</sub>), 115.57, 119.67, 120.62, 122.17, 123.04, 124.56, 124.73, 127.43, 127.63, 128.74, 130.81, 131.68, 132.92, 135.84, 142.18, 148.06, 148.21, 148.48, 149.75, 150.56, 150.69, 160.57 (C&#x02009;=&#x02009;O indolin-2-one), 165.06 (C&#x02009;=&#x02009;O hydrazide); IR (KBr, <italic>&#x003bd;</italic> cm<sup>&#x02212;1</sup>) 3334, 3270 (2NH) and 1728, 1707 (2&#x02009;C&#x02009;=&#x02009;O); Analysis calculated for C<sub>24</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>3</sub>: C, 58.91; H, 3.50; N, 11.45; found C, 59.22; H, 3.53; N, 11.52.</p></sec></sec></sec></sec><sec id="S0005-S2002" disp-level="2"><label>5.2.</label><title>Biological evaluations</title><p>All experimental procedures utilised in the biological assays herein conducted were performed as reported earlier; anti-proliferation<xref rid="CIT0115" ref-type="bibr"><sup>115</sup></xref>, cell cycle<xref rid="CIT0116" ref-type="bibr"><sup>116&#x02013;117</sup></xref>, Annexin V-FITC Apoptosis<xref rid="CIT0118" ref-type="bibr"><sup>118</sup></xref> and CDK2 kinase<xref rid="CIT0119" ref-type="bibr"><sup>119</sup></xref> assays, and have been provided in the <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2020.1862101">Supplementary Materials</ext-link>.</p></sec><sec id="S0005-S2003" disp-level="2"><label>5.3.</label><title>Molecular docking study</title><p>All the molecular modelling simulations were performed using Molecular Operating Environment (MOE, 2010.10) software. All minimizations were carried out with MOE until an RMSD gradient of 0.05&#x02009;kcal&#x000b7;mol<sup>&#x02212;1&#x02009;</sup>&#x000c5;<sup>&#x02212;1</sup> with MMFF94&#x000d7; force field and the partial charges were automatically calculated. The X-ray crystallographic structure of CDK2 co-crystallized with an oxindole derivative (IC<sub>50</sub> = 60&#x02009;nM) as inhibitor (PDB ID: 1FVT)<xref rid="CIT0109" ref-type="bibr"><sup>109</sup></xref> and of GSK-3&#x003b2; co-crystallized with the oxindole derivative Indirubin-3&#x02032;-monoxime (IC<sub>50</sub> = 22&#x02009;nM) as inhibitor (PDB ID: 1Q41)<xref rid="CIT0110" ref-type="bibr"><sup>110</sup></xref> were downloaded from the protein data bank<xref rid="CIT0120" ref-type="bibr"><sup>120</sup></xref>. The selection of these two protein structures specifically attributed to their co-crystallization with potent CDK2 and GSK-3&#x003b2; oxindole-based inhibitors, respectively.</p><p>For the CDK2 protein structure (PDB ID: 1FVT); water molecules were first removed, as for the GSK-3&#x003b2; protein structure (PDB ID: 1Q41); Chain B and water molecules which are not involved in binding were first removed, whereas, two conservative water molecules near chain A Thr138 that serve a functional role in the co-crystalized inhibitor binding were kept<xref rid="CIT0110" ref-type="bibr"><sup>110</sup></xref>. Then, the proteins were prepared for the docking study using <italic>LigX</italic> protocol in MOE with default options. The co-crystalized ligands were used to define the active site for docking. Triangle Matcher placement method and London dG scoring function were used for docking. Self-docking of the co-crystallized ligands in the active site of the kinase domains was first performed to validate the used docking protocol giving a docking pose with an energy score (S) = &#x02212;10.63&#x02009;kcal/mol and an RMSD of 0.894&#x02009;&#x000c5; in CDK2 (PDB ID: 1FVT) and energy score (S) = &#x02212;12.00&#x02009;kcal/mol and an RMSD of 0.471&#x02009;&#x000c5; in GSK-3&#x003b2; (PDB ID: 1Q41), <xref ref-type="fig" rid="F0007">Figure 7</xref> and <xref rid="t0005" ref-type="table">Table 5</xref>.</p><p>The validated docking protocols were then used to study the ligand-protein interactions of the newly synthesised compounds in the active site of the target kinases to predict their binding mode and establish their structure activity relationship (SAR) to rationalise their binding affinity.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM8866"><caption><title>Supplemental Material</title></caption><media xlink:href="IENZ_A_1862101_SM8866.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><sec id="S0006" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manning</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Whyte</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The protein kinase complement of the human genome</article-title>. <source>Science</source>
<year>2002</year>;<volume>298</volume>:<fpage>1912</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">12471243</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Parang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>G.</given-names></name></person-group>
<chapter-title>Protein kinase inhibitors drug discovery</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Gad</surname><given-names>SC</given-names></name></person-group>, ed. <source>Drug discovery handbook</source>. Hoboken, New Jersey: <publisher-name>John Wiley &#x00026; Sons, Inc</publisher-name>; <year>2005</year>:<fpage>1191</fpage>&#x02013;<lpage>1257</lpage>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roskoski</surname><given-names>R.</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</article-title>. <source>Pharmacol Res</source>
<year>2016</year>;<volume>103</volume>:<fpage>26</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">26529477</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allam</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Aly</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Farouk</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>98</volume>:<fpage>103726</fpage>.<pub-id pub-id-type="pmid">32171987</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Sanea</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Elkamhawy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Paik</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: synthesis, biological evaluation and in silico insights</article-title>. <source>Bioorg Med Chem</source>
<year>2020</year>;<volume>28</volume>:<fpage>115525</fpage>.<pub-id pub-id-type="pmid">32371117</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sasin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bottini</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protein tyrosine phosphatases in the human genome</article-title>. <source>Cell</source>
<year>2004</year>;<volume>117</volume>:<fpage>699</fpage>&#x02013;<lpage>711</lpage>.<pub-id pub-id-type="pmid">15186772</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bononi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Agnoletto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>De Marchi</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protein kinases and phosphatases in the control of cell fate</article-title>. <source>Enzyme Res</source>
<year>2011</year>;<volume>2011</volume>:<fpage>329098</fpage>.<pub-id pub-id-type="pmid">21904669</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>PL</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>NS.</given-names></name></person-group>
<article-title>Targeting cancer with small molecule kinase inhibitors</article-title>. <source>Nat Rev Cancer</source>
<year>2009</year>;<volume>9</volume>:<fpage>28</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">19104514</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabbro</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ruetz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Buchdunger</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protein kinases as targets for anticancer agents: from inhibitors to useful drugs</article-title>. <source>Pharmacol Ther</source>
<year>2002</year>;<volume>93</volume>:<fpage>79</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">12191602</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pearson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Garc&#x000ed;a-Echeverr&#x000ed;a</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fabbro</surname><given-names>D</given-names></name></person-group>, <chapter-title>Protein tyrosine kinases as targets for cancer and other indications</chapter-title> In: <person-group person-group-type="editor"><name name-style="western"><surname>Fabbro</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mc Cormick</surname><given-names>F</given-names></name></person-group>, eds. <source>Protein tyrosine kinases - from inhibitors to useful drugs</source>. <publisher-loc>Totowa (NJ)</publisher-loc>: <publisher-name>Humana Press Inc</publisher-name>; <year>2006</year>:<fpage>1</fpage>&#x02013;<lpage>29</lpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedlacek</surname><given-names>HH.</given-names></name></person-group>
<article-title>Kinase inhibitors in cancer therapy: a look ahead</article-title>. <source>Drugs</source>
<year>2000</year>;<volume>59</volume>:<fpage>435</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">10776829</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinstein</surname><given-names>IB</given-names></name>, <name name-style="western"><surname>Joe</surname><given-names>AK.</given-names></name></person-group>
<article-title>Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy</article-title>. <source>Nat Clin Pract Oncol</source>
<year>2006</year>;<volume>3</volume>:<fpage>448</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">16894390</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Padma</surname><given-names>VV.</given-names></name></person-group>
<article-title>An overview of targeted cancer therapy</article-title>. <source>BioMedicine</source>
<year>2015</year>;<volume>5</volume>:<fpage>19</fpage>.<pub-id pub-id-type="pmid">26613930</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggarwal</surname><given-names>S.</given-names></name></person-group>
<article-title>Targeted cancer therapies</article-title>. <source>Nat Rev Drug Discov</source>
<year>2010</year>;<volume>9</volume>:<fpage>427</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20514063</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topcul</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cetin</surname><given-names>I.</given-names></name></person-group>
<article-title>Endpoint of cancer treatment: targeted therapies</article-title>. <source>Asian Pac J Cancer Prev</source>
<year>2014</year>;<volume>15</volume>:<fpage>4395</fpage>&#x02013;<lpage>403</lpage>.<pub-id pub-id-type="pmid">24969859</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>
<year>2018</year>;<volume>68</volume>:<fpage>394</fpage>&#x02013;<lpage>424</lpage>.<pub-id pub-id-type="pmid">30207593</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="web"><person-group person-group-type="author"><collab>American Cancer Society</collab></person-group> Cancer Facts &#x00026; Figures <year>2019</year> Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf">https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf</ext-link>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>ZY</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Expression and prognostic significance of VEGFR-2 in breast cancer</article-title>. <source>Pathol Res Pract</source>
<year>2015</year>;<volume>211</volume>:<fpage>539</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">25976977</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Colbert</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Fuller</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Vascular endothelial growth factor receptor-2 in breast cancer</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1806</volume>:<fpage>108</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20462514</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Mohsen</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Abd El-Meguid</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer</article-title>. <source>Arch Pharm (Weinheim)</source>
<year>2020</year>;<volume>353</volume>:<fpage>e1900340</fpage>.<pub-id pub-id-type="pmid">32045054</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbauomy Elsheikh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Lambros</surname><given-names>MBK</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis</article-title>. <source>Breast Cancer Research</source>
<year>2007</year>;<volume>9</volume>:<fpage>R23</fpage>.<pub-id pub-id-type="pmid">17397528</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrekoussis</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stathopoulos</surname><given-names>EN</given-names></name>, <name name-style="western"><surname>Kafousi</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Expression of endothelial PDGF receptors alpha and beta in breast cancer: up-regulation of endothelial PDGF receptor beta</article-title>. <source>Oncol Rep</source>
<year>2007</year>;<volume>17</volume>:<fpage>1115</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17390053</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Xiang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zong</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in&#x000a0;vivo and in&#x000a0;vitro</article-title>. <source>Cancer Cell Int</source>
<year>2014</year>;<volume>14</volume>:<fpage>130</fpage>.<pub-id pub-id-type="pmid">25550687</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Karakas</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer</article-title>. <source>Oncotarget</source>
<year>2017</year>;<volume>8</volume>:<fpage>14897</fpage>&#x02013;<lpage>911</lpage>.<pub-id pub-id-type="pmid">28107181</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer</article-title>. <source>Int J Mol Sci</source>
<year>2020</year>;<volume>21</volume>:<fpage>1960</fpage>.</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harwell</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Danes</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Keyomarsi</surname><given-names>K.</given-names></name></person-group>
<article-title>Processing of cyclin E differs between normal and tumor breast cells</article-title>. <source>Cancer Res</source>
<year>2000</year>;<volume>60</volume>:<fpage>481</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10667604</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cooley</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zelivianski</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jeruss</surname><given-names>JS.</given-names></name></person-group>
<article-title>Impact of cyclin E overexpression on Smad3 activity in breast cancer cell lines</article-title>. <source>Cell Cycle</source>
<year>2010</year>;<volume>9</volume>:<fpage>4900</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">21150326</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quintayo</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Munro</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>GSK3&#x003b2; and cyclin D1 expression predicts outcome in early breast cancer patients</article-title>. <source>Breast Cancer Res Treat</source>
<year>2012</year>;<volume>136</volume>:<fpage>161</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">22976805</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walz</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ugolkov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chandra</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Molecular pathways: revisiting glycogen synthase Kinase-3&#x003b2; as a target for the treatment of cancer</article-title>. <source>Clin Cancer Res</source>
<year>2017</year>;<volume>23</volume>:<fpage>1891</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28053024</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duda</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Akula</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Abrams</surname><given-names>SL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting GSK3 and associated signaling pathways involved in cancer</article-title>. <source>Cells</source>
<year>2020</year>;<volume>9</volume>:<fpage>1110</fpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malumbres</surname><given-names>M.</given-names></name></person-group>
<article-title>Physiological relevance of cell cycle kinases</article-title>. <source>Physiol Rev</source>
<year>2011</year>;<volume>91</volume>:<fpage>973</fpage>&#x02013;<lpage>1007</lpage>.<pub-id pub-id-type="pmid">21742793</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malumbres</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Barbacid</surname><given-names>M.</given-names></name></person-group>
<article-title>Mammalian cyclin-dependent kinases</article-title>. <source>Trends Biochem Sci</source>
<year>2005</year>;<volume>30</volume>: <fpage>630</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">16236519</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapenna</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Giordano</surname><given-names>A.</given-names></name></person-group>
<article-title>Cell cycle kinases as therapeutic targets for cancer</article-title>. <source>Nat Rev Drug Discov</source>
<year>2009</year>;<volume>8</volume>:<fpage>547</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">19568282</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luk</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Simcox</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Schutt</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new series of potent oxindole inhibitors of CDK2</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2004</year>;<volume>14</volume>:<fpage>913</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15012993</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chohan</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Qayyum</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rehman</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers</article-title>. <source>Biomed Pharmacother</source>
<year>2018</year>;<volume>107</volume>:<fpage>1326</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">30257348</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chohan</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>JZ.</given-names></name></person-group>
<article-title>Cyclin-dependent kinase-2 as a target for cancer therapy: progress in the development of CDK2 inhibitors as anti-cancer agents</article-title>. <source>Curr Med Chem</source>
<year>2015</year>;<volume>22</volume>:<fpage>237</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">25386824</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd El-Karim</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Syam</surname><given-names>YM</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abdelghany</surname><given-names>TM.</given-names></name></person-group>
<article-title>New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: synthesis, CDK2 inhibition, QSAR and molecular docking studies</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>86</volume>:<fpage>80</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">30685646</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horiuchi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Huskey</surname><given-names>NE</given-names></name>, <name name-style="western"><surname>Kusdra</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>2012</year>;<volume>109</volume>: <fpage>E1019</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">22474407</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Heathcote</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Kroll</surname><given-names>SH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity</article-title>. <source>Cancer Res</source>
<year>2009</year>;<volume>69</volume>:<fpage>6208</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">19638587</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#x00119;sierska-G&#x00105;dek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gritsch</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zulehner</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-&#x003b1; in human ER-positive breast cancer cells</article-title>. <source>J Cell Biochem</source>
<year>2011</year>;<volume>112</volume>:<fpage>761</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">21328450</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bentley</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>LZ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells</article-title>. <source>Br J Cancer</source>
<year>2010</year>;<volume>102</volume>:<fpage>342</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">20010939</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welsh</surname><given-names>GI</given-names></name>, <name name-style="western"><surname>Proud</surname><given-names>CG.</given-names></name></person-group>
<article-title>Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B</article-title>. <source>Biochem J</source>
<year>1993</year>;<volume>294</volume>:<fpage>625</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8397507</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frame</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Biondi</surname><given-names>RM.</given-names></name></person-group>
<article-title>A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation</article-title>. <source>Mol Cell</source>
<year>2001</year>;<volume>7</volume>:<fpage>1321</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11430833</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hooper</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Killick</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lovestone</surname><given-names>S.</given-names></name></person-group>
<article-title>The GSK3 hypothesis of Alzheimer&#x02019;s disease</article-title>. <source>J Neurochem</source>
<year>2008</year>;<volume>104</volume>:<fpage>1433</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">18088381</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhat</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Budd Haeberlein</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Avila</surname><given-names>J.</given-names></name></person-group>
<article-title>Glycogen synthase kinase 3: a drug target for CNS therapies</article-title>. <source>J Neurochem</source>
<year>2004</year>;<volume>89</volume>:<fpage>1313</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15189333</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nikolakaki</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Plyte</surname><given-names>SE</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation</article-title>. <source>Embo J</source>
<year>1993</year>;<volume>12</volume>:<fpage>803</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">8382613</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martinez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Castro</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dorronsoro</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Alonso</surname><given-names>M.</given-names></name></person-group>
<article-title>Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation</article-title>. <source>Med Res Rev</source>
<year>2002</year>;<volume>22</volume>:<fpage>373</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">12111750</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avila</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Leon-Espinosa</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Garcia</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Tau phosphorylation by GSK3 in different conditions</article-title>. <source>Int J Alzheimers Dis</source>
<year>2012</year>;<volume>2012</volume>:<fpage>578373</fpage>.<pub-id pub-id-type="pmid">22675648</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doble</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Woodgett</surname><given-names>JR.</given-names></name></person-group>
<article-title>GSK-3: tricks of the trade for a multi-tasking kinase</article-title>. <source>J Cell Sci</source>
<year>2003</year>;<volume>116</volume>:<fpage>1175</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">12615961</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Osman</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Zaater</surname><given-names>MA.</given-names></name></person-group>
<article-title>Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3&#x003b2; inhibitors</article-title>. <source>J Mol Model</source>
<year>2019</year>;<volume>25</volume>:<fpage>171</fpage>.<pub-id pub-id-type="pmid">31129879</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaisina</surname><given-names>IN</given-names></name>, <name name-style="western"><surname>Gallier</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ougolkov</surname><given-names>AV</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells</article-title>. <source>J Med Chem</source>
<year>2009</year>;<volume>52</volume>:<fpage>1853</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">19338355</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugolkov</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gaisina</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>GSK-3 inhibition overcomes chemoresistance in human breast cancer</article-title>. <source>Cancer Lett</source>
<year>2016</year>;<volume>380</volume>:<fpage>384</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">27424289</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Branca</surname><given-names>MA.</given-names></name></person-group>
<article-title>Multi-kinase inhibitors create buzz at ASCO</article-title>. <source>Nat Biotechnol</source>
<year>2005</year>;<volume>23</volume>:<fpage>639</fpage>.<pub-id pub-id-type="pmid">15940222</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broekman</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Giovannetti</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>GJ.</given-names></name></person-group>
<article-title>Tyrosine kinase inhibitors: multi-targeted or single-targeted?</article-title>
<source>World J Clin Oncol</source>
<year>2011</year>;<volume>2</volume>:<fpage>80</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">21603317</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krug</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hilgeroth</surname><given-names>A.</given-names></name></person-group>
<article-title>Recent advances in the development of multi-kinase inhibitors</article-title>. <source>Mini Rev Med Chem</source>
<year>2008</year>;<volume>8</volume>:<fpage>1312</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">18991750</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller-Tidow</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Diederichs</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bulk</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer</article-title>. <source>Cancer Res</source>
<year>2005</year>;<volume>65</volume>:<fpage>1778</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">15753374</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garuti</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Roberti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bottegoni</surname><given-names>G.</given-names></name></person-group>
<article-title>Multi-kinase inhibitors</article-title>. <source>Curr Med Chem</source>
<year>2015</year>;<volume>22</volume>:<fpage>695</fpage>&#x02013;<lpage>712</lpage>.<pub-id pub-id-type="pmid">25511779</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Mohsen</surname><given-names>HT</given-names></name>, <name name-style="western"><surname>Omar</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>; <volume>179</volume>:<fpage>707</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">31284081</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lozinskaya</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Babkov</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Zaryanova</surname><given-names>EV</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3&#x003b2; inhibitors</article-title>. <source>Bioorg Med Chem</source>
<year>2019</year>;<volume>27</volume>:<fpage>1804</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">30902399</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouach</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boulahjar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vala</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>115</volume>:<fpage>311</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">27019296</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3&#x003b2; inhibitors: a critical review</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>164</volume>:<fpage>448</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">30616053</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boulahjar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ouach</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bourg</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>101</volume>:<fpage>274</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">26142492</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boulahjar</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ouach</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matteo</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts</article-title>. <source>J Med Chem</source>
<year>2012</year>;<volume>55</volume>:<fpage>9589</fpage>&#x02013;<lpage>606</lpage>.<pub-id pub-id-type="pmid">23083119</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polychronopoulos</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Magiatis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Skaltsounis</surname><given-names>AL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases</article-title>. <source>J Med Chem</source>
<year>2004</year>;<volume>47</volume>:<fpage>935</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">14761195</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mettey</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gompel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects</article-title>. <source>J Med Chem</source>
<year>2003</year>;<volume>46</volume>:<fpage>222</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">12519061</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3&#x003b2; (GSK-3&#x003b2;) phosphorylation inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>86</volume>:<fpage>165</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">25151579</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Dessalew</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Iqbal</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bharatam</surname><given-names>PV.</given-names></name></person-group>
<article-title>Structure-based approaches in the design of GSK-3 selective inhibitors</article-title>. <source>Curr Protein Pept Sci</source>
<year>2007</year>;<volume>8</volume>:<fpage>352</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">17696868</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arfeen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bharatam</surname><given-names>PV.</given-names></name></person-group>
<article-title>Molecular dynamics simulation studies of GSK-3&#x003b2; ATP competitive inhibitors: understanding the factors contributing to selectivity</article-title>. <source>J Biomol Struct Dyn</source>
<year>2015</year>;<volume>33</volume>:<fpage>2578</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26209183</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Echalier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Endicott</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Noble</surname><given-names>ME.</given-names></name></person-group>
<article-title>Recent developments in cyclin-dependent kinase biochemical and structural studies</article-title>. <source>Biochim Biophys Acta</source>
<year>2010</year>;<volume>1804</volume>:<fpage>511</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19822225</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>TG</given-names></name>, <name name-style="western"><surname>Tunnah</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Meijer</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate</article-title>. <source>Structure</source>
<year>2001</year>;<volume>9</volume>:<fpage>389</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">11377199</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Czelen</surname><given-names>P.</given-names></name></person-group>
<article-title>Inhibition mechanism of CDK-2 and GSK-3beta by a sulfamoylphenyl derivative of indoline-a molecular dynamics study</article-title>. <source>J Mol Model</source>
<year>2017</year>;<volume>23</volume>:<fpage>230</fpage>.<pub-id pub-id-type="pmid">28726150</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pacureanu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Avram</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bora</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Portraying the selectivity of GSK-3 inhibitors towards CDK-2 by 3D similarity and molecular docking</article-title>. <source>Struct Chem</source>
<year>2019</year>;<volume>30</volume>:<fpage>911</fpage>&#x02013;<lpage>23</lpage>.</mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>EY</given-names></name>, <name name-style="western"><surname>Chiu</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A hierarchical phosphorylation cascade that regulates the timing of PERIOD nuclear entry reveals novel roles for proline-directed kinases and GSK-3beta/SGG in circadian clocks</article-title>. <source>J Neurosci</source>
<year>2010</year>;<volume>30</volume>:<fpage>12664</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">20861372</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Garnier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hoessel</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer&#x02019;s disease. A property common to most cyclin-dependent kinase inhibitors?</article-title>
<source>J Biol Chem</source>
<year>2001</year>;<volume>276</volume>:<fpage>251</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">11013232</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhat</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Berg</surname><given-names>S</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418</article-title>. <source>J Biol Chem</source>
<year>2003</year>;<volume>278</volume>:<fpage>45937</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">12928438</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vine</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Matesic</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Locke</surname><given-names>JM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cytotoxic and anticancer activities of isatin and its derivatives: a comprehensive review from 2000&#x02013;2008</article-title>. <source>Anticancer Agents Med Chem</source>
<year>2009</year>;<volume>9</volume>:<fpage>397</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">19442041</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Aziz</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Keeton</surname><given-names>AB</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in&#x000a0;vitro pharmacological profiling</article-title>. <source>Drug Des Devel Ther</source>
<year>2017</year>;<volume>11</volume>:<fpage>2333</fpage>&#x02013;<lpage>46</lpage>.</mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Warhi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Aljaeed</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, biological evaluation and in silico studies of certain oxindole-indole conjugates as anticancer CDK inhibitors</article-title>. <source>Molecules</source>
<year>2020</year>;<volume>25</volume>:<fpage>2031</fpage>.</mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodman</surname><given-names>VL</given-names></name>, <name name-style="western"><surname>Rock</surname><given-names>EP</given-names></name>, <name name-style="western"><surname>Dagher</surname><given-names>R</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma</article-title>. <source>Clin Cancer Res</source>
<year>2007</year>;<volume>13</volume>:<fpage>1367</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">17332278</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inomata</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nishioka</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Azuma</surname><given-names>A.</given-names></name></person-group>
<article-title>Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis</article-title>. <source>Core Evid</source>
<year>2015</year>;<volume>10</volume>:<fpage>89</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">26346347</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagtap</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>PT</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>85</volume>:<fpage>268</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">25089810</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yousefian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ghodsi</surname><given-names>R.</given-names></name></person-group>
<article-title>Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents</article-title>. <source>Arch Pharm (Weinheim)</source>
<year>2020</year>;<volume>353</volume>:<fpage>e2000022</fpage>.<pub-id pub-id-type="pmid">32885522</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>El Kerdawy</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Al-Ansary</surname><given-names>GH</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>163</volume>:<fpage>37</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30503942</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laufer</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Forrest</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>SW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>6069</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">23829549</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Jagtap</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>PT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bioisosteric replacement of an acylureido moiety attached to an indolin-2-one scaffold with a malonamido or a 2/4-pyridinoylamido moiety produces a selectively potent Aurora-B inhibitor</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>84</volume>:<fpage>312</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">25036791</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Substituted indolin-2-ones as p90 ribosomal S6 protein kinase 2 (RSK2) inhibitors: molecular docking simulation and structure-activity relationship analysis</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>1724</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">23434140</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aneja</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>163</volume>:<fpage>840</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">30579124</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dweedar</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Mahrous</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Abdel-Aziz</surname><given-names>HA.</given-names></name></person-group>
<article-title>Analogue-based design, synthesis and biological evaluation of 3-substituted-(methylenehydrazono)indolin-2-ones as anticancer agents</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>78</volume>:<fpage>275</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">24686014</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoessel</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Leclerc</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Endicott</surname><given-names>JA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases</article-title>. <source>Nat Cell Biol</source>
<year>1999</year>;<volume>1</volume>:<fpage>60</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">10559866</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damiens</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Baratte</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Marie</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest</article-title>. <source>Oncogene</source>
<year>2001</year>;<volume>20</volume>:<fpage>3786</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">11439342</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marko</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schatzle</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Friedel</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells</article-title>. <source>Br J Cancer</source>
<year>2001</year>;<volume>84</volume>:<fpage>283</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">11161389</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, in&#x000a0;vitro and in&#x000a0;vivo antitumor activity of symmetrical bis-Schiff base derivatives of isatin</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>74</volume>:<fpage>742</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">24176732</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meijer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Skaltsounis</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Magiatis</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>GSK-3-selective inhibitors derived from Tyrian purple indirubins</article-title>. <source>Chem Biol</source>
<year>2003</year>;<volume>10</volume>:<fpage>1255</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">14700633</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanam</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shamsuzzaman</surname><given-names>&#x000a0;</given-names></name></person-group>, <article-title>Bioactive Benzofuran derivatives: a review</article-title>. <source>Eur J Med Chem</source>
<year>2015</year>;<volume>97</volume>:<fpage>483</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">25482554</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>Y-h</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y-h</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Natural source, bioactivity and synthesis of benzofuran derivatives</article-title>. <source>RSC Adv</source>
<year>2019</year>;<volume>9</volume>:<fpage>27510</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="CIT0096"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Georgey</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>George</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Mohamed</surname><given-names>ER.</given-names></name></person-group>
<article-title>Aurones and furoaurones: biological activities and synthesis</article-title>. <source>Bull Faculty Pharm Cairo Univ</source>
<year>2018</year>;<volume>56</volume>:<fpage>121</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0097"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Elsayed</surname><given-names>ZM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzofuran-based carboxylic acids as carbonic anhydrase inhibitors and antiproliferative agents against breast cancer</article-title>. <source>ACS Med Chem Lett</source>
<year>2020</year>;<volume>11</volume>:<fpage>1022</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">32435420</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hirth</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Asmussen</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>3050</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21507633</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salom&#x000e9;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Narbonne</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzofuran derivatives as a novel class of inhibitors of mTOR signaling</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>74</volume>:<fpage>41</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24445311</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salom&#x000e9;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chavagnan</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzofuran derivatives as anticancer inhibitors of mTOR signaling</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>81</volume>:<fpage>181</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">24836070</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abd El-Karim</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Anwar</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Mohamed</surname><given-names>NA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents</article-title>. <source>Bioorg Chem</source>
<year>2015</year>;<volume>63</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26368040</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mosmann</surname><given-names>T.</given-names></name></person-group>
<article-title>Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays</article-title>. <source>J Immunol Methods</source>
<year>1983</year>;<volume>65</volume>:<fpage>55</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="CIT0103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cherukupalli</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chandrasekaran</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Krystof</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2018</year>;<volume>79</volume>:<fpage>46</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">29753773</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oakes</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Harrington</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle</article-title>. <source>Cell Cycle</source>
<year>2014</year>;<volume>13</volume>:<fpage>3302</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">25485510</pub-id></mixed-citation></ref><ref id="CIT0105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Odajima</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>SL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1)</article-title>. <source>Cancer Cell</source>
<year>2005</year>;<volume>7</volume>:<fpage>591</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">15950907</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acikgoz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Guler</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Camlar</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Glycogen synthase kinase-3 inhibition in glioblastoma multiforme cells induces apoptosis, cell cycle arrest and changing biomolecular structure</article-title>. <source>Spectrochim Acta A Mol Biomol Spectrosc</source>
<year>2019</year>;<volume>209</volume>:<fpage>150</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">30388586</pub-id></mixed-citation></ref><ref id="CIT0107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rashid</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Mazur</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Analysis of the role of GSK3 in the mitotic checkpoint</article-title>. <source>Sci Rep</source>
<year>2018</year>;<volume>8</volume>:<fpage>14259</fpage>.<pub-id pub-id-type="pmid">30250048</pub-id></mixed-citation></ref><ref id="CIT0108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorczyca</surname><given-names>W.</given-names></name></person-group>
<article-title>Cytometric analyses to distinguish death processes</article-title>. <source>Endocr Relat Cancer</source>
<year>1999</year>;<volume>6</volume>:<fpage>17</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10732781</pub-id></mixed-citation></ref><ref id="CIT0109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Benson</surname><given-names>BG</given-names></name>, <name name-style="western"><surname>Bramson</surname><given-names>HN</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors</article-title>. <source>Science</source>
<year>2001</year>;<volume>291</volume>:<fpage>134</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11141566</pub-id></mixed-citation></ref><ref id="CIT0110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertrand</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Thieffine</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vulpetti</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors</article-title>. <source>J Mol Biol</source>
<year>2003</year>;<volume>333</volume>:<fpage>393</fpage>&#x02013;<lpage>407</lpage>.<pub-id pub-id-type="pmid">14529625</pub-id></mixed-citation></ref><ref id="CIT0111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attia</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Afifi</surname><given-names>SA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres</article-title>. <source>Plos One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0181241</fpage>.<pub-id pub-id-type="pmid">28742842</pub-id></mixed-citation></ref><ref id="CIT0112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Nocentini</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>157</volume>:<fpage>28</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">30071407</pub-id></mixed-citation></ref><ref id="CIT0113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Khanapure</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H-O</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Efficient synthesis of a benzo[b]furan building block</article-title>. <source>Synth Commun</source>
<year>2010</year>;<volume>40</volume>:<fpage>3390</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Abo-Ashour</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>HS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel [(3-indolylmethylene)hydrazono]indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in&#x000a0;vitro biological evaluation</article-title>. <source>J Enzyme Inhibit Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>686</fpage>&#x02013;<lpage>700</lpage>.</mixed-citation></ref><ref id="CIT0115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abdelhafez</surname><given-names>OM</given-names></name>, <name name-style="western"><surname>El-Haggar</surname><given-names>RS</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in&#x000a0;vitro biological evaluation, and QSAR studies</article-title>. <source>J Enzyme Inhibit Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>1095</fpage>&#x02013;<lpage>107</lpage>.</mixed-citation></ref><ref id="CIT0116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahdy</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Ibrahim</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Metwaly</surname><given-names>AM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, molecular modeling, in&#x000a0;vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>94</volume>:<fpage>103422</fpage>.<pub-id pub-id-type="pmid">31812261</pub-id></mixed-citation></ref><ref id="CIT0117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Al-Rashood</surname><given-names>ST</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and in&#x000a0;vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents</article-title>. <source>J Enzyme Inhibit Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>322</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="CIT0118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmetwally</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Saied</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Eissa</surname><given-names>IH</given-names></name>, <name name-style="western"><surname>Elkaeed</surname><given-names>EB.</given-names></name></person-group>
<article-title>Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers</article-title>. <source>Bioorgan Chem</source>
<year>2019</year>;<volume>88</volume>:<fpage>102944</fpage>.</mixed-citation></ref><ref id="CIT0119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eldehna</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Al-Warhi</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights</article-title>. <source>J Enzyme Inhibit Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1616</fpage>&#x02013;<lpage>30</lpage>.</mixed-citation></ref><ref id="CIT0120"><label>120</label><mixed-citation publication-type="web">Protein Data Bank. <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/">https://www.rcsb.org/</ext-link> [last accessed10 Oct 2020].</mixed-citation></ref></ref-list></back></article>